<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OSENI- alogliptin benzoate and pioglitazone hydrochloride tablet, film coated </strong><br>Takeda Pharmaceuticals America, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use OSENI safely and effectively. See full prescribing information for OSENI.<br> <br>OSENI (alogliptin and pioglitazone) tablets<br>Initial U.S. Approval: 2013</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span></h1>
<h1 class="Warning"><span class="Bold">See full prescribing information for complete boxed warning</span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">Thiazolidinediones, including pioglitazone, cause or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in some patients. (<a href="#i4i_section_ID_s5.1">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">After initiation of OSENI and after dose increases, monitor patients carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (e.g., excessive, rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> and/or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>). If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone in OSENI must be considered.</span></dd>
<dt>•</dt>
<dd><span class="Bold">OSENI is not recommended in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</span></dd>
<dt>•</dt>
<dd><span class="Bold">Initiation of OSENI in patients with established New York Heart Association (NYHA) Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated. (<a href="#i4i_contraindications_ID_s4">4</a>, <a href="#i4i_section_ID_s5.1">5.1</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> </p>
<p class="Highlighta">Warnings and Precautions (<a href="#ID_f568e9df-d5a6-4bd5-a82f-0347c427bd0c">5.11</a>)                         8/2015 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span></h1>
<h1 class="Warning"><span class="Bold">See full prescribing information for complete boxed warning</span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">Thiazolidinediones, including pioglitazone, cause or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in some patients. (<a href="#i4i_section_ID_s5.1">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">After initiation of OSENI and after dose increases, monitor patients carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (e.g., excessive, rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> and/or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>). If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone in OSENI must be considered.</span></dd>
<dt>•</dt>
<dd><span class="Bold">OSENI is not recommended in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</span></dd>
<dt>•</dt>
<dd><span class="Bold">Initiation of OSENI in patients with established New York Heart Association (NYHA) Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated. (<a href="#i4i_contraindications_ID_s4">4</a>, <a href="#i4i_section_ID_s5.1">5.1</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">OSENI is a dipeptidyl peptidase-4 inhibitor and thiazolidinedione combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. (<a href="#i4i_section_ID_s1.1">1.1</a>) </p>
<p class="Highlighta">  </p>
<p class="Highlighta">Limitation of Use: Not for treatment of type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. (<a href="#i4i_section_ID_s1.2">1.2</a>) </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<dl>
<dt>•</dt>
<dd>Individualize the starting dose of OSENI based on the patient’s current regimen and concurrent medical condition but do not exceed a daily dose of alogliptin 25 mg and pioglitazone 45 mg.</dd>
<dt>•</dt>
<dd>Can be taken with or without food. (<a href="#i4i_section_ID_s2.1">2.1</a>)</dd>
<dt>•</dt>
<dd>Limit initial dose of pioglitazone to 15 mg once daily in patients with NYHA Class I or II <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#i4i_section_ID_s2.1">2.1</a>)</dd>
<dt>•</dt>
<dd>Adjust dose if moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#i4i_section_ID_s2.2">2.2</a>)</dd>
</dl>
<table width="100%">
<col width="25%">
<col width="28%">
<col width="47%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="bottom"><p class="Highlighta"><span class="Bold">Degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span> </p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="Highlighta"><span class="Bold">Creatinine Clearance (mL/min)</span> </p></td>
<td class="Botrule Toprule" align="center" valign="bottom"><p class="Highlighta"><span class="Bold">Recommended Dosing</span> </p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="middle"><p class="Highlighta">Moderate </p></td>
<td class="Botrule" align="center" valign="middle"><p class="Highlighta">≥30 to &lt;60 </p></td>
<td class="Botrule" align="center" valign="middle">
<p class="Highlighta">12.5 mg/15 mg,  </p>
<p class="Highlighta">12.5 mg/30 mg or  </p>
<p class="Highlighta">12.5 mg/45 mg once daily </p>
</td>
</tr>
</tbody>
</table>
<dl>
<dt>•</dt>
<dd>OSENI is not recommended for patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) requiring dialysis. (<a href="#i4i_section_ID_s2.2">2.2</a>)</dd>
<dt>•</dt>
<dd>The maximum recommended dose of pioglitazone is 15 mg once daily in patients taking strong CYP2C8 inhibitors (e.g., gemfibrozil). (<a href="#i4i_section_ID_s2.5">2.3</a>, <a href="#i4i_section_ID_s7.1">7.1</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Tablets: </p>
<p class="Highlighta">25 mg alogliptin and 15 mg pioglitazone, 25 mg alogliptin and 30 mg pioglitazone, 25 mg alogliptin and 45 mg pioglitazone. (<a href="#i4i_dosage_form_strength_ID_s3">3</a>) </p>
<p class="Highlighta">12.5 mg alogliptin and 15 mg pioglitazone, 12.5 mg alogliptin and 30 mg pioglitazone, 12.5 mg alogliptin and 45 mg pioglitazone. (<a href="#i4i_dosage_form_strength_ID_s3">3</a>) </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>History of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to alogliptin or pioglitazone, components of OSENI, such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> or severe cutaneous adverse reactions. (<a href="#i4i_contraindications_ID_s4">4</a>)</dd>
<dt>•</dt>
<dd>Do not initiate OSENI in patients with established NYHA Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#i4i_contraindications_ID_s4">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span>: <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> may occur and can exacerbate or lead to <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Combination use with insulin and use in <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> NYHA Class I and II may increase risk. Monitor patients for signs and symptoms. (<a href="#i4i_section_ID_s5.1">5.1</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">Acute pancreatitis</span>: There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>. If <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> is suspected, promptly discontinue OSENI. (<a href="#i4i_section_ID_s5.2">5.2</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: There have been postmarketing reports of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> in patients treated with alogliptin such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and severe cutaneous adverse reactions. In such cases, promptly discontinue OSENI, assess for other potential causes, institute appropriate monitoring and treatment and initiate alternative treatment for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. (<a href="#i4i_section_ID_s5.3">5.3</a>)</dd>
<dt>•</dt>
<dd>Hepatic effects: Postmarketing reports of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, sometimes fatal. Causality cannot be excluded. If <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is detected, promptly interrupt OSENI and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart OSENI if <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is confirmed and no alternative etiology can be found. Use with caution in patients with liver disease. (<a href="#i4i_section_ID_s5.4">5.4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>: Dose-related <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> may occur. (<a href="#i4i_section_ID_s5.5">5.5</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span>: Increased incidence in female patients. Apply current standards of care for assessing and maintaining bone health. (<a href="#i4i_section_ID_s5.6">5.6</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">Bladder cancer</span>: Preclinical and clinical trial data, and results from an observational study suggest an increased risk of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> in pioglitazone users. The observational data further suggest that the risk increases with duration of use. Do not use in patients with active <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>. Use caution when using in patients with a prior history of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>. (<a href="#i4i_section_ID_s5.7">5.7</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>: When an insulin secretagogue (e.g., sulfonylurea) or insulin is used in combination with OSENI, a lower dose of insulin secretagogue or insulin may be required to minimize the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. (<a href="#i4i_section_ID_s5.8">5.8</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span>: Postmarketing reports. Recommend regular eye exams in all patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> according to current standards of care with prompt evaluation for acute visual changes. (<a href="#i4i_section_ID_s5.9">5.9</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>: Severe and disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> has been reported in patients taking DPP-4 inhibitors. Consider as a possible cause for severe <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> and discontinue if appropriate. (<a href="#ID_f568e9df-d5a6-4bd5-a82f-0347c427bd0c">5.11</a>)</dd>
<dt>•</dt>
<dd>Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with OSENI or any other antidiabetic drug. (<a href="#ID_1da978bb-8dda-483c-b0d3-127b265b8f13">5.12</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Common adverse reactions reported in ≥4% of patients treated with coadministration of alogliptin 25 mg and pioglitazone 15 mg, 30 mg or 45 mg were <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> and <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>. (<a href="#i4i_section_ID_s6.1">6.1</a>) </p>
<p class="Highlighta">  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Strong CYP2C8 inhibitors (e.g., gemfibrozil) increase pioglitazone concentrations. Limit the pioglitazone dose to 15 mg daily. (<a href="#i4i_section_ID_s2.5">2.3</a>, <a href="#i4i_section_ID_s7.1">7.1</a>)</dd>
<dt>•</dt>
<dd>CYP2C8 inducers (e.g., rifampin) may decrease pioglitazone concentrations. (<a href="#i4i_section_ID_s7.2">7.2</a>)</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Nursing mothers: Discontinue drug or nursing, taking into consideration the importance of the drug to the mother. (<a href="#i4i_nursing_mothers_ID_s8.3">8.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 8/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Monotherapy and Combination Therapy</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Limitation of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommendations for All Patients</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Coadministration with Strong CYP2C8 Inhibitors</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Hepatic Effects</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Urinary Bladder Tumors</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Use with Medications Known to Cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Ovulation</a></h2>
<h2><a href="#section-5.11" class="toc"><span class="XmChange">5.11 Severe and Disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Macrovascular Outcomes</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Laboratory Abnormalities</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Strong CYP2C8 Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 CYP2C8 Inducers</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Instructions</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="i4i_boxed_warning_ID_box"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">Thiazolidinediones, including pioglitazone, which is a component of OSENI, cause or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in some patients <span class="Italics">[see <a href="#i4i_section_ID_s5.1">Warnings and Precautions (5.1)</a>]</span>.</span></dd>
<dt>•</dt>
<dd><span class="Bold">After initiation of OSENI and after dose increases, monitor patients carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (e.g., excessive, rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> and/or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>). If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone in OSENI must be considered.</span></dd>
<dt>•</dt>
<dd><span class="Bold">OSENI is not recommended in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</span></dd>
<dt>•</dt>
<dd><span class="Bold">Initiation of OSENI in patients with established New York Heart Association (NYHA) Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated <span class="Italics">[see <a href="#i4i_contraindications_ID_s4">Contraindications (4)</a></span> and <span class="Italics"><a href="#i4i_section_ID_s5.1">Warnings and Precautions (5.1)</a>]</span>.</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Monotherapy and Combination Therapy</h2>
<p class="First">OSENI is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in multiple clinical settings when treatment with both alogliptin and pioglitazone is appropriate <span class="Italics">[see <a href="#i4i_clinical_studies_ID_s14">Clinical Studies (14)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Limitation of Use</h2>
<p class="First">OSENI should not be used in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or for the treatment of <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>, as it would not be effective in these settings.</p>
<p>Use with caution in patients with liver disease <span class="Italics">[see <a href="#i4i_section_ID_s5.4">Warnings and Precautions (5.4)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommendations for All Patients</h2>
<p class="First">OSENI should be taken once daily and can be taken with or without food. The tablets must not be split before swallowing.</p>
<p>The recommended starting dose for OSENI (alogliptin and pioglitazone):</p>
<dl>
<dt>•</dt>
<dd>for patients inadequately controlled on diet and exercise is 25 mg/15 mg or 25 mg/30 mg,</dd>
<dt>•</dt>
<dd>for patients inadequately controlled on metformin monotherapy is 25 mg/15 mg or 25 mg/30 mg,</dd>
<dt>•</dt>
<dd>for patients on alogliptin who require additional glycemic control is 25 mg/15 mg or 25 mg/30 mg,</dd>
<dt>•</dt>
<dd>for patients on pioglitazone who require additional glycemic control is 25 mg/15 mg, 25 mg/30 mg or 25 mg/45 mg as appropriate based upon current therapy,</dd>
<dt>•</dt>
<dd>for patients switching from alogliptin coadministered with pioglitazone, OSENI may be initiated at the dose of alogliptin and pioglitazone based upon current therapy,</dd>
<dt>•</dt>
<dd>for patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (NYHA Class I or II) is 25 mg/15 mg.</dd>
</dl>
<p>The OSENI dose can be titrated up to a maximum of 25 mg/45 mg once daily based on glycemic response as determined by hemoglobin A1c (A1C).</p>
<p>After initiation of OSENI or with dose increase, monitor patients carefully for adverse reactions related to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> as has been seen with pioglitazone (e.g., <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and signs and symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>) <span class="Italics">[see <a href="#i4i_boxed_warning_ID_box">Boxed Warning</a> and <a href="#i4i_section_ID_s5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dose adjustment of OSENI is necessary for patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance [CrCl] ≥60 mL/min).</p>
<p>The dose of OSENI is 12.5 mg/15 mg, 12.5 mg/30 mg or 12.5 mg/45 mg once daily for patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl ≥30 to &lt;60 mL/min).</p>
<p>OSENI is not recommended for patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or ESRD <span class="Italics">[see <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>]</span>. Coadministration of pioglitazone and alogliptin 6.25 mg once daily based on individual requirements may be considered in these patients.</p>
<p>Because there is a need for dose adjustment based upon renal function, assessment of renal function is recommended prior to initiation of OSENI therapy and periodically thereafter.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s2.5"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Coadministration with Strong CYP2C8 Inhibitors</h2>
<p class="First">Coadministration of pioglitazone and gemfibrozil, a strong CYP2C8 inhibitor, increases pioglitazone exposure approximately three-fold. Therefore, the maximum recommended dose of OSENI is 25 mg/15 mg daily when used in combination with gemfibrozil or other strong CYP2C8 inhibitors <span class="Italics">[see <a href="#i4i_section_ID_s7.1">Drug Interactions (7.1)</a> and <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_ID_s3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<dl>
<dt>•</dt>
<dd>25 mg/15 mg tablets are yellow, round, biconvex, and film-coated, with both "A/P" and "25/15" printed on one side.</dd>
<dt>•</dt>
<dd>25 mg/30 mg tablets are peach, round, biconvex, and film-coated, with both "A/P" and "25/30" printed on one side.</dd>
<dt>•</dt>
<dd>25 mg/45 mg tablets are red, round, biconvex, and film-coated, with both "A/P" and "25/45" printed on one side.</dd>
<dt>•</dt>
<dd>12.5 mg/15 mg tablets are <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, round, biconvex, and film-coated, with both "A/P" and "12.5/15" printed on one side.</dd>
<dt>•</dt>
<dd>12.5 mg/30 mg tablets are <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> peach, round, biconvex, and film-coated, with both "A/P" and "12.5/30" printed on one side.</dd>
<dt>•</dt>
<dd>12.5 mg/45 mg tablets are <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> red, round, biconvex, and film-coated, with both "A/P" and "12.5/45" printed on one side.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_ID_s4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">History of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to alogliptin or pioglitazone, components of OSENI, such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> or severe cutaneous adverse reactions.</p>
<p>Do not initiate in patients with NYHA Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> <span class="Italics">[see <a href="#i4i_boxed_warning_ID_box">Boxed Warning</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_ID_s5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></h2>
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p>Pioglitazone, like other thiazolidinediones, can cause dose-related <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> when used alone or in combination with other antidiabetic medications and is most common when pioglitazone is used in combination with insulin. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> may lead to or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Patients should be observed for signs and symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. If <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> develops, it should be managed according to current standards of care and discontinuation or dose reduction of pioglitazone must be considered <span class="Italics">[see <a href="#i4i_boxed_warning_ID_box">Boxed Warning</a>, <a href="#i4i_contraindications_ID_s4">Contraindications (4)</a> and <a href="#i4i_section_ID_s6.1">Adverse Reactions (6.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h2>
<p class="First">There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span> in patients taking alogliptin. After initiation of OSENI, patients should be observed carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. If <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> is suspected, OSENI should promptly be discontinued and appropriate management should be initiated. It is unknown whether patients with a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> are at increased risk for the development of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> while using OSENI.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">There have been postmarketing reports of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> in patients treated with alogliptin. These reactions include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and severe cutaneous adverse reactions, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>. If a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected, discontinue OSENI, assess for other potential causes for the event and institute alternative treatment for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> <span class="Italics">[see <a href="#i4i_section_ID_s6.3">Adverse Reactions (6.3)</a>]</span>. Use caution in patients with a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> to another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> with OSENI.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Hepatic Effects</h2>
<p class="First">There have been postmarketing reports of fatal and nonfatal hepatic events in patients taking pioglitazone or alogliptin, although the reports contain insufficient information necessary to establish the probable cause <span class="Italics">[see <a href="#i4i_section_ID_s6.3">Adverse Reactions (6.3)</a>]</span>. There has been no evidence of drug-induced hepatotoxicity in the pioglitazone controlled clinical trial database to date <span class="Italics">[see <a href="#i4i_section_ID_s6.1">Adverse Reactions (6.1)</a>]</span>. In randomized controlled studies of alogliptin, serum <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT) elevations greater than three times the upper limit of normal (ULN) were observed: 1.3% in alogliptin-treated patients and 1.5% in all comparator-treated patients.</p>
<p>Patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> may have <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">fatty liver</span> disease or cardiac disease with episodic <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, both of which may cause liver test abnormalities, and they may also have other forms of liver disease, many of which can be treated or managed. Therefore, obtaining a liver test panel (ALT, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> [AST], alkaline phosphatase and total bilirubin) and assessing the patient is recommended before initiating OSENI therapy. In patients with abnormal liver tests, OSENI should be initiated with caution.</p>
<p>Measure liver tests promptly in patients who report symptoms that may indicate <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, including <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, right <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">upper abdominal discomfort</span>, dark urine or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. In this clinical context, if the patient is found to have abnormal liver tests (ALT greater than three times the upper limit of the reference range), OSENI treatment should be interrupted and an investigation done to establish the probable cause. OSENI should not be restarted in these patients without another explanation for the liver test abnormalities.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p>In controlled clinical trials, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> was reported more frequently in patients treated with pioglitazone than in placebo-treated patients and is dose-related <span class="Italics">[see <a href="#i4i_section_ID_s6.1">Adverse Reactions (6.1)</a>]. </span>In postmarketing experience, reports of new onset or worsening of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been received.</p>
<p>OSENI should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. Because thiazolidinediones, including pioglitazone, can cause <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, which can exacerbate or lead to <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, OSENI should be used with caution in patients at risk for <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Patients treated with OSENI should be monitored for signs and symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> <span class="Italics">[see <a href="#i4i_boxed_warning_ID_box">Boxed Warning</a></span>, <span class="Italics"><a href="#i4i_section_ID_s5.1">Warnings and Precautions (5.1)</a></span> and <span class="Italics"><a href="#i4i_section_ID_s17.1">Patient Counseling Information (17.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span></h2>
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p>In PROactive (the Prospective Pioglitazone Clinical Trial in Macrovascular Events), 5238 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and a history of macrovascular disease were randomized to pioglitazone (N=2605), force-titrated up to 45 mg daily or placebo (N=2633) in addition to standard of care. During a mean follow-up of 34.5 months, the incidence of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> in females was 5.1% (44/870) for pioglitazone versus 2.5% (23/905) for placebo. This difference was noted after the first year of treatment and persisted during the course of the study. The majority of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> observed in female patients were nonvertebral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> including lower limb and distal upper limb. No increase in the incidence of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> was observed in men treated with pioglitazone (1.7%) versus placebo (2.1%). The risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> should be considered in the care of patients, especially female patients, treated with pioglitazone and attention should be given to assessing and maintaining bone health according to current standards of care.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Urinary Bladder Tumors</h2>
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p>Tumors were observed in the urinary bladder of male rats in the two-year carcinogenicity study <span class="Italics">[see <a href="#i4i_carcinogenesis_mutagenesis_fertility_ID_s13.1">Nonclinical Toxicology (13.1)</a>]</span>. In two 3-year trials in which pioglitazone was compared to placebo or glyburide, there were 16/3656 (0.44%) reports of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> in patients taking pioglitazone compared to 5/3679 (0.14%) in patients not taking pioglitazone. After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>, there were six (0.16%) cases on pioglitazone and two (0.05%) cases on placebo.</p>
<p>A five-year interim report of an ongoing 10-year observational cohort study found a nonsignificant increase in the risk for <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> in subjects ever exposed to pioglitazone, compared to subjects never exposed to pioglitazone (HR 1.2 [95% CI 0.9–1.5]). Compared to never exposure, a duration of pioglitazone therapy longer than 12 months was associated with an increase in risk (HR 1.4 [95% CI 0.9–2.1]), which reached statistical significance after more than 24 months of pioglitazone use (HR 1.4 [95% CI 1.03–2.0]). Interim results from this study suggested that taking pioglitazone longer than 12 months increased the relative risk of developing <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> in any given year by 40%, which equates to an absolute increase of three cases in 10,000 (from approximately seven in 10,000 [without pioglitazone] to approximately 10 in 10,000 [with pioglitazone]).</p>
<p>There are insufficient data to determine whether pioglitazone is a tumor promoter for urinary bladder tumors. Consequently, pioglitazone should not be used in patients with active <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> and the benefits of glycemic control versus unknown risks for cancer recurrence with pioglitazone should be considered in patients with a prior history of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Use with Medications Known to Cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First">Insulin and insulin secretagogues, such as sulfonylureas, are known to cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> when used in combination with OSENI<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span></h2>
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span> has been reported in postmarketing experience in diabetic patients who were taking pioglitazone or another thiazolidinedione. Some patients presented with <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> or decreased visual acuity, but others were diagnosed on routine ophthalmologic examination.</p>
<p>Most patients had <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> at the time <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span> was diagnosed. Some patients had improvement in their <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span> after discontinuation of their thiazolidinedione.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> should have regular eye exams by an ophthalmologist according to current standards of care. Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> who report any visual symptoms should be promptly referred to an ophthalmologist, regardless of the patient's underlying medications or other physical findings<span class="Italics"> [see <a href="#i4i_section_ID_s6.1">Adverse Reactions (6.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_051ac787-c59c-46c1-ac17-40cd12079981"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Ovulation</h2>
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p>Therapy with pioglitazone, like other thiazolidinediones, may result in ovulation in some premenopausal anovulatory women. As a result, these patients may be at an increased risk for pregnancy while taking OSENI <span class="Italics">[see <a href="#i4i_pregnancy_ID_s8.1">Use in Specific Populations (8.1)</a>]</span>. This effect has not been investigated in clinical trials, so the frequency of this occurrence is not known. Adequate contraception in all premenopausal women treated with OSENI is recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f568e9df-d5a6-4bd5-a82f-0347c427bd0c"></a><a name="section-5.11"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.11 Severe and Disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">There have been postmarketing reports of severe and disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> in patients taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of symptoms upon discontinuation of the medication. A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP-4 inhibitor. Consider DPP-4 inhibitors as a possible cause for severe <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> and discontinue drug if appropriate.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1da978bb-8dda-483c-b0d3-127b265b8f13"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Macrovascular Outcomes</h2>
<p class="First">There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with OSENI or any other antidiabetic drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_s6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p><span class="Bold">Alogliptin and Pioglitazone</span></p>
<p>Over 1500 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> have received alogliptin coadministered with pioglitazone in four large, randomized, double-blind, controlled clinical trials. The mean exposure to OSENI was 29 weeks with more than 100 subjects treated for more than one year. The studies consisted of two placebo-controlled studies of 16 to 26 weeks in duration and two active-controlled studies of 26 weeks and 52 weeks in duration. In the OSENI arm, the mean duration of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> was approximately six years, the mean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI) was 31 kg/m<span class="Sup">2</span> (54% of patients had a BMI ≥30 kg/m<span class="Sup">2</span>), and the mean age was 54 years (16% of patients ≥65 years of age).</p>
<p>In a pooled analysis of these four controlled clinical studies, the overall incidence of adverse events was 65% in patients treated with OSENI compared to 57% treated with placebo. Overall discontinuation of therapy due to adverse events was 2.5% with OSENI compared to 2.0% with placebo, 3.7% with pioglitazone or 1.3% with alogliptin.</p>
<p>Adverse reactions reported in ≥4% of patients treated with OSENI and more frequently than in patients who received alogliptin, pioglitazone or placebo are summarized in <span class="Italics">Table 1</span>.</p>
<table width="100%">
<col width="37%">
<col width="13%">
<col width="17%">
<col width="20%">
<col width="13%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>OSENI – includes data pooled for patients receiving alogliptin 25 mg and 12.5 mg combined with pioglitazone 15 mg, 30 mg and 45 mg</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Alogliptin – includes data pooled for patients receiving alogliptin 25 mg and 12.5 mg</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Pioglitazone – includes data pooled for patients receiving pioglitazone 15 mg, 30 mg and 45 mg</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="5" valign="top"><p class="First"><span class="Bold">Table 1. Adverse Reactions Reported in ≥4% of Patients Treated with OSENI and More Frequently than in Patients Receiving Either Alogliptin, Pioglitazone or Placebo</span></p></td></tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="5" valign="top"><p class="First"><span class="Bold">Number of Patients (%)</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">OSENI</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Alogliptin</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Pioglitazone</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=1533</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=446</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=949</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=153</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">75 (4.9)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">21 (4.7)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">37 (3.9)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6 (3.9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">64 (4.2)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">9 (2.0)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">32 (3.4)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5 (3.3)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">63 (4.1)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">19 (4.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">26 (2.7)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5 (3.3)</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics">Alogliptin Add-On Therapy to a Thiazolidinedione</span></span></p>
<p>In addition, in a 26-week, placebo-controlled, double-blind study, patients inadequately controlled on a thiazolidinedione alone or in combination with metformin or a sulfonylurea were treated with add-on alogliptin therapy or placebo; the adverse reactions reported in ≥5% of patients and more frequently than in patients who received placebo was <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span> (alogliptin, 5.5%; placebo, 4.1%).</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span></p>
<p>In a 26-week, placebo-controlled factorial study with alogliptin in combination with pioglitazone on background therapy with metformin, the incidence of subjects reporting <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 0.8%, 0% and 3.8% for alogliptin 25 mg with pioglitazone 15 mg, 30 mg or 45 mg, respectively; 2.3% for alogliptin 25 mg; 4.7%, 0.8% and 0.8% for pioglitazone 15 mg, 30 mg or 45 mg, respectively; and 0.8% for placebo.</p>
<p>In a 26-week, active-controlled, double-blind study with alogliptin alone, pioglitazone alone or alogliptin coadministered with pioglitazone in patients inadequately controlled on diet and exercise, the incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 3% on alogliptin 25 mg with pioglitazone 30 mg, 0.6% on alogliptin 25 mg and 1.8% on pioglitazone 30 mg.</p>
<p>In a 52-week, active-controlled, double-blind study of alogliptin as add-on therapy to the combination of pioglitazone 30 mg and metformin compared to the titration of pioglitazone 30 mg to 45 mg and metformin, the incidence of subjects reporting <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 4.5% in the alogliptin 25 mg with pioglitazone 30 mg and metformin group versus 1.5% in the pioglitazone 45 mg and metformin group.</p>
<p><span class="Bold">Alogliptin</span></p>
<p>Approximately 8500 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> have been treated with alogliptin in 14 randomized, double-blind, controlled clinical trials with approximately 2900 subjects randomized to placebo and approximately 2200 to an active comparator. The mean exposure to alogliptin was 40 weeks with more than 2400 subjects treated for more than one year. Among these patients, 63% had a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, 51% had a history of <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, 25% had a history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, 8% had a history of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> and 7% had a history of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. The mean duration of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> was seven years, the mean BMI was 31 kg/m<span class="Sup">2 </span>(51% of patients had a BMI ≥30 kg/m<span class="Sup">2</span>) and the mean age was 57 years (24% of patients ≥65 years of age).</p>
<p>Two placebo-controlled monotherapy trials of 12 and 26 weeks in duration were conducted in patients treated with alogliptin 12.5 mg daily, alogliptin 25 mg daily and placebo. Four placebo-controlled add-on combination therapy trials of 26 weeks in duration were also conducted: with metformin, with a sulfonylurea, with a thiazolidinedione and with insulin.</p>
<p>Four placebo-controlled and one active-controlled trials of 16 weeks up through two years in duration were conducted in combination with metformin, in combination with pioglitazone and with pioglitazone added to a background of metformin therapy.</p>
<p>Three active-controlled trials of 52 weeks in duration were conducted in patients treated with pioglitazone and metformin, in combination with metformin and as monotherapy compared to glipizide.</p>
<p>In a pooled analysis of these 14 controlled clinical trials, the overall incidence of adverse events was 66% in patients treated with alogliptin 25 mg compared to 62% with placebo and 70% with active comparator. Overall discontinuation of therapy due to adverse events was 4.7% with alogliptin 25 mg compared to 4.5% with placebo or 6.2% with active comparator.</p>
<p>Adverse reactions reported in ≥4% of patients treated with alogliptin 25 mg and more frequently than in patients who received placebo are summarized in <span class="Italics">Table 2</span>.</p>
<table width="100%">
<col width="40%">
<col width="20%">
<col width="20%">
<col width="20%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="4" valign="top"><p class="First"><span class="Bold">Table 2. Adverse Reactions Reported in ≥4% Patients Treated with Alogliptin 25 mg and More Frequently than in Patients Given Placebo in Pooled Studies</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="3" valign="middle"><p class="First"><span class="Bold">Number of Patients (%)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Alogliptin 25 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Active Comparator</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=5902</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=2926</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=2257</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">257 (4.4)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">89 (3.0)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">113 (5.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">247 (4.2)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">72 (2.5)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">121 (5.4)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">247 (4.2)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">61 (2.1)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">113 (5.0)</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></span></p>
<p>In the clinical trial program, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> was reported in 11 of 5902 (0.2%) patients receiving alogliptin 25 mg daily compared to five of 5183 (&lt;0.1%) patients receiving all comparators.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></p>
<p>In a pooled analysis, the overall incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> was 0.6% with alogliptin 25 mg compared to 0.8% with all comparators. A single event of <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span> was reported in a patient treated with alogliptin 25 mg.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span></p>
<p>Hypoglycemic events were documented based upon a blood glucose value and/or clinical signs and symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
<p>In the monotherapy study, the incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 1.5% in patients treated with alogliptin compared to 1.6% with placebo. The use of alogliptin as add-on therapy to glyburide or insulin did not increase the incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> compared to placebo. In a monotherapy study comparing alogliptin to a sulfonylurea in elderly patients, the incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 5.4% with alogliptin compared to 26% with glipizide.</p>
<p><span class="Bold">Pioglitazone</span></p>
<p>Over 8500 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> have been treated with pioglitazone in randomized, double-blind, controlled clinical trials, including 2605 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and macrovascular disease treated with pioglitazone in the PROactive clinical trial. In these trials, over 6000 patients have been treated with pioglitazone for six months or longer, over 4500 patients have been treated with pioglitazone for one year or longer, and over 3000 patients have been treated with pioglitazone for at least two years.</p>
<p><span class="Bold"><span class="Italics">Common Adverse Events: 16- to 26-Week Monotherapy Trials</span></span></p>
<p>A summary of the incidence and type of common adverse events reported in three pooled 16- to 26-week placebo-controlled monotherapy trials of pioglitazone is provided in <span class="Italics">Table 3</span>. Terms that are reported represent those that occurred at an incidence of &gt;5% and more commonly in patients treated with pioglitazone than in patients who received placebo. None of these adverse events were related to pioglitazone dose.</p>
<table width="100%">
<col width="53%">
<col width="23%">
<col width="23%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First"><span class="Bold">Table 3. Three Pooled 16- to 26-Week Placebo-Controlled Clinical Trials of Pioglitazone Monotherapy: Adverse Events Reported at an Incidence &gt;5% and More Commonly in Patients Treated with Pioglitazone than in Patients Treated with Placebo</span></p></td></tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3" valign="middle"><p class="First"><span class="Bold">% of Patients</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span><br>N=259</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Pioglitazone</span><br>N=606</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">13.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">9.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">2.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5.4</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5.1</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></span></span></p>
<p>A summary of the incidence of adverse events related to <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> for the 16- to 24-week add-on to sulfonylurea trials, for the 16- to 24-week add-on to insulin trials, and for the 16- to 24-week add-on to metformin trials were (at least one <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, 0.2% to 1.7%; hospitalized due to <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, 0.2% to 0.9%). None of the events were fatal.</p>
<p>Patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and NYHA class II or early class III <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> were randomized to receive 24 weeks of double-blind treatment with either pioglitazone at daily doses of 30 mg to 45 mg (N=262) or glyburide at daily doses of 10 mg to 15 mg (N=256). A summary of the incidence of adverse events related to <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> reported in this study is provided in <span class="Italics">Table 4</span>.</p>
<table width="100%">
<col width="50%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First"><span class="Bold">Table 4. Treatment-Emergent Adverse Events of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> (CHF) in Patients with NYHA Class II or III <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> Treated with Pioglitazone or Glyburide</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First"><span class="Bold">Number (%) of Subjects</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Pioglitazone</span><br>N=262</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Glyburide</span><br>N=256</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to cardiovascular causes (adjudicated)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5 (1.9%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6 (2.3%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Overnight hospitalization for worsening CHF (adjudicated)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">26 (9.9%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">12 (4.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Emergency room visit for CHF (adjudicated)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4 (1.5%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">3 (1.2%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Patients experiencing CHF progression during study</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">35 (13.4%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">21 (8.2%)</p></td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> events leading to hospitalization that occurred during the PROactive trial are summarized in <span class="Italics">Table 5</span>.</p>
<table width="100%">
<col width="51%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First"><span class="Bold">Table 5. Treatment-Emergent Adverse Events of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> (CHF) in PROactive Trial</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First"><span class="Bold">Number (%) of Patients</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span><br>N=2633</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Pioglitazone</span><br>N=2605</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">At least one hospitalized <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> event</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">108 (4.1%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">149 (5.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Fatal</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">22 (0.8%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">25 (1%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Hospitalized, nonfatal</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">86 (3.3%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">124 (4.7%)</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Underline">Cardiovascular Safety</span></span></p>
<p>In the PROactive trial, 5238 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and a history of macrovascular disease were randomized to pioglitazone (N=2605), force-titrated up to 45 mg daily or placebo (N=2633) in addition to standard of care. Almost all patients (95%) were receiving cardiovascular medications (beta blockers, ACE inhibitors, angiotensin II receptor blockers, calcium channel blockers, nitrates, diuretics, aspirin, statins and fibrates). At baseline, patients had a mean age of 62 years, mean duration of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> of 9.5 years and mean A1C of 8.1%. Mean duration of follow-up was 34.5 months.</p>
<p>The primary objective of this trial was to examine the effect of pioglitazone on mortality and macrovascular morbidity in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus who were at high risk for macrovascular events. The primary efficacy variable was the time to the first occurrence of any event in a cardiovascular composite endpoint that included all-cause mortality, nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) including silent MI, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span>, cardiac intervention including coronary artery bypass grafting or percutaneous intervention, major leg amputation above the ankle and bypass surgery or revascularization in the leg. A total of 514 (19.7%) patients treated with pioglitazone and 572 (21.7%) placebo-treated patients experienced at least one event from the primary composite endpoint (hazard ratio 0.90; 95% Confidence Interval: 0.80, 1.02; p=0.10).</p>
<p>Although there was no statistically significant difference between pioglitazone and placebo for the three-year incidence of a first event within this composite, there was no increase in mortality or in total macrovascular events with pioglitazone. The number of first occurrences and total individual events contributing to the primary composite endpoint is shown in <span class="Italics">Table 6</span>.</p>
<table width="100%">
<col width="48%">
<col width="14%">
<col width="13%">
<col width="13%">
<col width="13%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="5" valign="top"><p class="First"><span class="Bold">Table 6. PROactive: Number of First and Total Events for Each Component Within the Cardiovascular Composite Endpoint</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Cardiovascular Events</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First"><span class="Bold">Placebo</span><br>N=2633</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First"><span class="Bold">Pioglitazone</span><br>N=2605</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">First Events<br>n (%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">Total Events<br>n</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">First Events<br>n (%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">Total Events<br>n</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Any Event</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">572 (21.7)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">900</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">514 (19.7)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">803</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  All-Cause Mortality</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">122 (4.6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">186</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">110 (4.2)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">177</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span> (MI)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">118 (4.5)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">157</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">105 (4)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">131</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">96 (3.6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">119</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">76 (2.9)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">92</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">Acute Coronary Syndrome</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">63 (2.4)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">78</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">42 (1.6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">65</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Cardiac Intervention (CABG/PCI)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">101 (3.8)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">240</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">101 (3.9)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">195</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Major Leg Amputation</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">15 (0.6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">28</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">9 (0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">28</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Leg Revascularization</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">57 (2.2)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">92</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">71 (2.7)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">115</p></td>
</tr>
<tr class="Last"><td class="Botrule" colspan="5" valign="top"><p class="First">CABG=coronary artery bypass grafting; PCI=percutaneous intervention</p></td></tr>
</tbody>
</table>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span></span></p>
<p>Dose-related <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> occurs when pioglitazone is used alone or in combination with other antidiabetic medications. The mechanism of <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> is unclear but probably involves a combination of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> and fat accumulation.</p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></span></span></p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> induced from taking pioglitazone is reversible when pioglitazone is discontinued. The <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> usually does not require hospitalization unless there is coexisting <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
<p><span class="Bold"><span class="Underline">Hepatic Effects</span></span></p>
<p>There has been no evidence of pioglitazone-induced hepatotoxicity in the pioglitazone controlled clinical trial database to date. One randomized, double-blind, three-year trial comparing pioglitazone to glyburide as add-on to metformin and insulin therapy was specifically designed to evaluate the incidence of serum ALT elevation to greater than three times the upper limit of the reference range, measured every eight weeks for the first 48 weeks of the trial then every 12 weeks thereafter. A total of 3/1051 (0.3%) patients treated with pioglitazone and 9/1046 (0.9%) patients treated with glyburide developed ALT values greater than three times the upper limit of the reference range. None of the patients treated with pioglitazone in the pioglitazone controlled clinical trial database to date have had a serum ALT greater than three times the upper limit of the reference range and a corresponding total bilirubin greater than two times the upper limit of the reference range, a combination predictive of the potential for severe drug-induced <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>.</p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span></span></p>
<p>In the pioglitazone clinical trials, adverse events of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> were reported based on clinical judgment of the investigators and did not require confirmation with fingerstick glucose testing. In the 16-week add-on to sulfonylurea trial, the incidence of reported <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 3.7% with pioglitazone 30 mg and 0.5% with placebo. In the 16-week add-on to insulin trial, the incidence of reported <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 7.9% with pioglitazone 15 mg, 15.4% with pioglitazone 30 mg and 4.8% with placebo. The incidence of reported <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was higher with pioglitazone 45 mg compared to pioglitazone 30 mg in both the 24-week add-on to sulfonylurea trial (15.7% versus 13.4%) and in the 24-week add-on to insulin trial (47.8% versus 43.5%). Three patients in these four trials were hospitalized due to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. All three patients were receiving pioglitazone 30 mg (0.9%) in the 24-week add-on to insulin trial. An additional 14 patients reported severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (defined as causing considerable interference with patient's usual activities) that did not require hospitalization. These patients were receiving pioglitazone 45 mg in combination with sulfonylurea (N=2) or pioglitazone 30 mg or 45 mg in combination with insulin (N=12).</p>
<p><span class="Bold"><span class="Underline">Urinary Bladder Tumors</span></span></p>
<p>Tumors were observed in the urinary bladder of male rats in the two-year carcinogenicity study <span class="Italics">[see <a href="#i4i_carcinogenesis_mutagenesis_fertility_ID_s13.1">Nonclinical Toxicology (13.1)</a>].</span> In two 3-year trials in which pioglitazone was compared to placebo or glyburide, there were 16/3656 (0.44%) reports of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> in patients taking pioglitazone compared to 5/3679 (0.14%) in patients not taking pioglitazone. After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>, there were six (0.16%) cases on pioglitazone and two (0.05%) cases on placebo. There are too few events of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> to establish causality.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Laboratory Abnormalities</h2>
<p class="First"><span class="Bold">Alogliptin</span></p>
<p>No clinically meaningful changes in hematology, serum chemistry or urinalysis were observed in patients treated with alogliptin.</p>
<p><span class="Bold">Pioglitazone</span></p>
<p><span class="Bold"><span class="Italics">Hematologic Effects</span></span></p>
<p>Pioglitazone may cause decreases in hemoglobin and hematocrit. In placebo-controlled monotherapy trials, mean hemoglobin values declined by 2% to 4% in patients treated with pioglitazone compared with a mean change in hemoglobin of -1% to +1% in placebo-treated patients. These changes primarily occurred within the first four to 12 weeks of therapy and remained relatively constant thereafter. These changes may be related to increased plasma volume associated with pioglitazone therapy and are not likely to be associated with any clinically significant hematologic effects.</p>
<p><span class="Bold"><span class="Italics">Creatine Phosphokinase</span></span></p>
<p>During protocol-specified measurement of serum creatine phosphokinase (CPK) in pioglitazone clinical trials, an isolated elevation in CPK to greater than 10 times the upper limit of the reference range was noted in nine (0.2%) patients treated with pioglitazone (values of 2150 to 11400 IU/L) and in no comparator-treated patients. Six of these nine patients continued to receive pioglitazone, two patients were noted to have the CPK elevation on the last day of dosing and one patient discontinued pioglitazone due to the elevation. These elevations resolved without any apparent clinical sequelae. The relationship of these events to pioglitazone therapy is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First"><span class="Bold">Alogliptin</span></p>
<p>The following adverse reactions have been identified during the postmarketing use of alogliptin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and severe cutaneous adverse reactions, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, hepatic enzyme elevations, <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">fulminant hepatic failure</span>, severe and disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> and <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>. <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_ID_s5.2">5.2</a>, <a href="#i4i_section_ID_s5.3">5.3</a>, <a href="#i4i_section_ID_s5.4">5.4</a>, <a href="#ID_f568e9df-d5a6-4bd5-a82f-0347c427bd0c">5.11</a>)]</span>.</p>
<p><span class="Bold">Pioglitazone</span></p>
<p>The following adverse reactions have been identified during the postmarketing use of pioglitazone. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>New onset or worsening <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">diabetic macular edema</span> with decreased visual acuity <span class="Italics">[see <a href="#i4i_section_ID_s5.9">Warnings and Precautions (5.9)</a>]</span>.</p>
<p>Fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> <span class="Italics">[see <a href="#i4i_section_ID_s5.4">Warnings and Precautions (5.4)</a>].</span></p>
<p>Postmarketing reports of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> have been reported in patients treated with pioglitazone, both with and without previously known heart disease and both with and without concomitant insulin administration.</p>
<p>In postmarketing experience, there have been reports of unusually rapid increases in weight and increases in excess of that generally observed in clinical trials. Patients who experience such increases should be assessed for fluid accumulation and volume-related events such as excessive <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> <span class="Italics">[see <a href="#i4i_boxed_warning_ID_box">Boxed Warning</a> and <a href="#i4i_section_ID_s5.1">Warnings and Precautions (5.1)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_ID_s7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><span class="Bold">Alogliptin</span></p>
<p>Alogliptin is primarily renally excreted. Cytochrome (CYP) P450-related metabolism is negligible. No significant drug-drug interactions were observed with the CYP-substrates or inhibitors tested or with renally excreted drugs <span class="Italics">[see <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Strong CYP2C8 Inhibitors</h2>
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p>An inhibitor of CYP2C8 (e.g., gemfibrozil) significantly increases the exposure (area under the concentration-time curve [AUC]) and half-life of pioglitazone. Therefore, the maximum recommended dose of pioglitazone is 15 mg daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors <span class="Italics">[see <a href="#i4i_section_ID_s2.5">Dosage and Administration (2.3)</a> and <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 CYP2C8 Inducers</h2>
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p>An inducer of CYP2C8 (e.g., rifampin) may significantly decrease the exposure (AUC) of pioglitazone. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with OSENI, changes in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> treatment may be needed based on clinical response without exceeding the maximum recommended daily dose of 45 mg for pioglitazone <span class="Italics">[see <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_ID_s8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_ID_s8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category C</span></p>
<p><span class="Bold"><span class="Italics">Alogliptin and Pioglitazone</span></span></p>
<p>There are no adequate and well-controlled studies in pregnant women with OSENI or its individual components. Based on animal data, the likelihood that OSENI increases the risk of developmental abnormalities is predicted to be low. OSENI should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>When administered to rats during organogenesis, the combination treatment with alogliptin and pioglitazone (100 mg/kg alogliptin plus 40 mg/kg pioglitazone) slightly augmented pioglitazone-related fetal effects of delayed development and reduced fetal weights but did not result in embryofetal mortality or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.</p>
<p><span class="Bold"><span class="Italics">Alogliptin</span></span></p>
<p>Alogliptin administered to pregnant rabbits and rats during the period of organogenesis was not teratogenic at doses of up to 200 and 500 mg/kg, or 149 times and 180 times, respectively, the clinical dose based on plasma drug exposure (AUC).</p>
<p>Doses of alogliptin up to 250 mg/kg (approximately 95 times clinical exposure based on AUC) given to pregnant rats from gestation Day 6 to lactation Day 20 did not harm the developing embryo or adversely affect growth and development of offspring.</p>
<p>Placental transfer of alogliptin into the fetus was observed following oral dosing to pregnant rats.</p>
<p><span class="Bold"><span class="Italics">Pioglitazone</span></span></p>
<p>In animal reproductive studies, pregnant rats and rabbits received pioglitazone at doses up to approximately 17 (rat) and 40 (rabbit) times the MRHD based on body surface area (mg/m<span class="Sup">2</span>); no <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed. Increases in embryotoxicity (increased postimplantation losses, delayed development, reduced fetal weights and delayed parturition) occurred in rats that received oral doses approximately 10 or more times the MRHD (mg/m<span class="Sup">2</span> basis). No functional or behavioral toxicity was observed in rat offspring. When pregnant rats received pioglitazone during late gestation and lactation, delayed postnatal development, attributed to decreased body weight, occurred in rat offspring at oral maternal doses approximately two or more times the MRHD (mg/m<span class="Sup">2</span> basis). In rabbits, embryotoxicity occurred at oral doses approximately 40 times the MRHD (mg/m<span class="Sup">2</span> basis).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_ID_s8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">No studies have been conducted with the combined components of OSENI. In studies performed with the individual components, both alogliptin and pioglitazone are secreted in the milk of lactating rats. It is not known whether alogliptin and/or pioglitazone are secreted in human milk. Because many drugs are excreted in human milk, and because of the potential for OSENI to cause serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue OSENI, taking into account the importance of OSENI to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_s8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of OSENI in pediatric patients have not been established.</p>
<p>OSENI is not recommended for use in pediatric patients based on adverse effects observed in adults, including <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> and urinary bladder tumors <span class="Italics">[see <a href="#i4i_section_ID_s5.7">Warnings and Precautions (5.1, 5.5, 5.6, 5.7)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_ID_s8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First"><span class="Bold">Alogliptin and Pioglitazone</span></p>
<p>Of the total number of patients (N=1533) in clinical safety and efficacy studies treated with alogliptin and pioglitazone, 248 (16.2%) patients were 65 years and older and 15 (1%) patients were 75 years and older. No overall differences in safety or effectiveness were observed between these patients and younger patients. While this and other reported clinical experiences have not identified differences in responses between the elderly and younger patients, greater sensitivity of some older individuals cannot be excluded.</p>
<p><span class="Bold">Alogliptin</span></p>
<p>Of the total number of patients (N=8507) in clinical safety and efficacy studies treated with alogliptin, 2064 (24.3%) patients were ≥65 years old and 341 (4%) patients were ≥75 years old. No overall differences in safety or effectiveness were observed between patients ≥65 years old and younger patients.</p>
<p><span class="Bold">Pioglitazone</span></p>
<p>A total of 92 patients (15.2%) treated with pioglitazone in the three pooled, 16- to 26-week, double-blind, placebo-controlled, monotherapy trials were ≥65 years old and two patients (0.3%) were ≥75 years old. In the two pooled 16- to 24-week add-on to sulfonylurea trials, 201 patients (18.7%) treated with pioglitazone were ≥65 years old and 19 (1.8%) were ≥75 years old. In the two pooled 16- to 24-week add-on to metformin trials, 155 patients (15.5%) treated with pioglitazone were ≥65 years old and 19 (1.9%) were ≥75 years old. In the two pooled 16- to 24-week add-on to insulin trials, 272 patients (25.4%) treated with pioglitazone were ≥65 years old and 22 (2.1%) were ≥75 years old.</p>
<p>In PROactive, 1068 patients (41%) treated with pioglitazone were ≥65 years old and 42 (1.6%) were ≥75 years old.</p>
<p>In pharmacokinetic studies with pioglitazone, no significant differences were observed in pharmacokinetic parameters between elderly and younger patients. These clinical experiences have not identified differences in effectiveness and safety between the elderly (≥65 years) and younger patients although small sample sizes for patients ≥75 years old limit conclusions <span class="Italics">[see <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_eb87414d-9583-48e9-a91a-abf8c14c194c"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First"><span class="Bold">Alogliptin</span></p>
<p>No dose adjustments are required in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Grade A and B) based on insignificant change in systemic exposures (e.g., AUC) compared to subjects with normal hepatic function in a pharmacokinetic study. Alogliptin has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Grade C). Use caution when administering alogliptin to patients with liver disease <span class="Italics">[see <a href="#i4i_section_ID_s5.4">Warnings and Precautions (5.4)</a>].</span></p>
<p><span class="Bold">Pioglitazone</span></p>
<p>No dose adjustments are required in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Grade B and C) based on insignificant change in systemic exposures (e.g., AUC) compared to subjects with normal hepatic function in a pharmacokinetic study. However, use with caution in patients with liver disease <span class="Italics">[see <a href="#i4i_section_ID_s5.4">Warnings and Precautions (5.4)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_s10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><span class="Bold">Alogliptin</span></p>
<p>The highest doses of alogliptin administered in clinical trials were single doses of 800 mg to healthy subjects and doses of 400 mg once daily for 14 days to patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (equivalent to 32 times and 16 times the maximum recommended clinical dose of 25 mg, respectively). No serious adverse events were observed at these doses.</p>
<p>In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, it is reasonable to institute the necessary clinical monitoring and supportive therapy as dictated by the patient's clinical status. Per clinical judgment, it may be reasonable to initiate removal of unabsorbed material from the gastrointestinal tract.</p>
<p>Alogliptin is minimally dialyzable; over a three-hour hemodialysis session, approximately 7% of the drug was removed. Therefore, hemodialysis is unlikely to be beneficial in an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situation. It is not known if alogliptin is dialyzable by peritoneal dialysis.</p>
<p><span class="Bold">Pioglitazone</span></p>
<p>During controlled clinical trials, one case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with pioglitazone was reported. A male patient took 120 mg per day for four days, then 180 mg per day for seven days. The patient denied any clinical symptoms during this period.</p>
<p>In the event of overdosage, appropriate supportive treatment should be initiated according to patient's clinical signs and symptoms.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_s11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">OSENI tablets contain two oral antihyperglycemic drugs used in the management of type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>: alogliptin and pioglitazone.</p>
<p><span class="Bold">Alogliptin</span></p>
<p>Alogliptin is a selective, orally bioavailable inhibitor of the enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt, which is identified as 2-({6-[(3<span class="Italics">R</span>)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2<span class="Italics">H</span>)-yl}methyl)benzonitrile monobenzoate. It has a molecular formula of C<span class="Sub">18</span>H<span class="Sub">21</span>N<span class="Sub">5</span>O<span class="Sub">2</span>•C<span class="Sub">7</span>H<span class="Sub">6</span>O<span class="Sub">2</span> and a molecular weight of 461.51 daltons. The structural formula is:</p>
<div class="Figure">
<a name="id7311575"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55&amp;name=image-01.jpg">
</div>
<p>Alogliptin benzoate is a white to off-white crystalline powder that contains one asymmetric carbon in the aminopiperidine moiety. It is soluble in dimethylsulfoxide, sparingly soluble in water and methanol, slightly soluble in ethanol and very slightly soluble in octanol and isopropyl acetate.</p>
<p><span class="Bold">Pioglitazone</span></p>
<p>Pioglitazone is an oral antihyperglycemic agent that acts primarily by decreasing <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span>. Chemically, pioglitazone is prepared as hydrochloride salt, which is identified as (±)-5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione monohydrochloride. It has a molecular formula of C<span class="Sub">19</span>H<span class="Sub">20</span>N<span class="Sub">2</span>O<span class="Sub">3</span>S•HCl and a molecular weight of 392.90 daltons. The structural formula is:</p>
<div class="Figure">
<a name="id7312345"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55&amp;name=95b44edb-bd6f-471b-a1c7-44694551ecae-02.jpg">
</div>
<p>Pioglitazone hydrochloride is an odorless white crystalline powder that contains one asymmetric carbon in the thiazolidinedione moiety. The synthetic compound is a racemate and the two enantiomers of pioglitazone interconvert <span class="Italics">in vivo</span>. It is soluble in <span class="Italics">N,N</span> dimethylformamide, slightly soluble in anhydrous ethanol, very slightly soluble in acetone and acetonitrile, practically insoluble in water and insoluble in ether.</p>
<p>OSENI is available as a fixed-dose combination tablet for oral administration containing 34 mg alogliptin benzoate equivalent to 25 mg alogliptin and any of the following strengths of pioglitazone hydrochloride:</p>
<dl>
<dt>•</dt>
<dd>16.53 mg pioglitazone hydrochloride equivalent to 15 mg pioglitazone (25 mg/15 mg)</dd>
<dt>•</dt>
<dd>33.06 mg pioglitazone hydrochloride equivalent to 30 mg pioglitazone (25 mg/30 mg)</dd>
<dt>•</dt>
<dd>49.59 mg pioglitazone hydrochloride equivalent to 45 mg pioglitazone (25 mg/45 mg)</dd>
</dl>
<p>OSENI is also available as a fixed-dose combination tablet for oral administration containing 17 mg alogliptin benzoate equivalent to 12.5 mg alogliptin and any of the following strengths of pioglitazone hydrochloride:</p>
<dl>
<dt>•</dt>
<dd>16.53 mg pioglitazone hydrochloride equivalent to 15 mg pioglitazone (12.5 mg/15 mg)</dd>
<dt>•</dt>
<dd>33.06 mg pioglitazone hydrochloride equivalent to 30 mg pioglitazone (12.5 mg/30 mg)</dd>
<dt>•</dt>
<dd>49.59 mg pioglitazone hydrochloride equivalent to 45 mg pioglitazone (12.5 mg/45 mg)</dd>
</dl>
<p>OSENI tablets contain the following inactive ingredients: mannitol, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, magnesium stearate and lactose monohydrate; the tablets are film-coated with hypromellose, polyethylene glycol, titanium dioxide, talc and ferric oxide (yellow and/or red) and are marked with printing ink (Red A1 or Gray F1).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_s12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_ID_s12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">OSENI combines two antihyperglycemic agents with complementary and distinct mechanisms of action to improve glycemic control in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>: alogliptin, a selective inhibitor of DPP-4, and pioglitazone, a member of the TZD class.</p>
<p><span class="Bold">Alogliptin</span></p>
<p>Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals. These hormones cause insulin release from the pancreatic beta cells in a glucose-dependent manner but are inactivated by the DPP-4 enzyme within minutes. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production. In patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, concentrations of GLP-1 are reduced but the insulin response to GLP-1 is preserved. Alogliptin is a DPP-4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. Alogliptin selectively binds to and inhibits DPP-4 but not DPP-8 or DPP-9 activity <span class="Italics">in vitro</span> at concentrations approximating therapeutic exposures.</p>
<p><span class="Bold">Pioglitazone</span></p>
<p>Pharmacologic studies indicate that pioglitazone improves insulin sensitivity in muscle and adipose tissue while inhibiting hepatic gluconeogenesis. Unlike sulfonylureas, pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPARγ). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle and liver. Activation of PPARγ nuclear receptors modulates the transcription of a number of insulin-responsive genes involved in the control of glucose and lipid metabolism.</p>
<p>In animal models of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, pioglitazone reduces the <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinemia</span> and <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> characteristic of insulin-resistant states such as type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. The metabolic changes produced by pioglitazone result in increased responsiveness of insulin-dependent tissues and are observed in numerous animal models of <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span>.</p>
<p>Because pioglitazone enhances the effects of circulating insulin (by decreasing <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span>), it does not lower blood glucose in animal models that lack endogenous insulin.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_ID_s12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Bold">Alogliptin and Pioglitazone</span></p>
<p>In a 26-week, randomized, active-controlled study, patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> received alogliptin 25 mg coadministered with pioglitazone 30 mg, alogliptin 12.5 mg coadministered with pioglitazone 30 mg, alogliptin 25 mg alone or pioglitazone 30 mg alone. Patients who were randomized to alogliptin 25 mg with pioglitazone 30 mg achieved a 26.2% decrease in triglyceride levels from a mean baseline of 214.2 mg/dL compared to an 11.5% decrease for alogliptin alone and a 21.8% decrease for pioglitazone alone. In addition, a 14.4% increase in HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels from a mean baseline of 43.2 mg/dL was also observed for alogliptin 25 mg with pioglitazone 30 mg compared to a 1.9% increase for alogliptin alone and a 13.2% increase for pioglitazone alone. The changes in measures of LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> were similar between alogliptin 25 mg with pioglitazone 30 mg versus alogliptin alone and pioglitazone alone. A similar pattern of lipid effects was observed in a 26-week, placebo-controlled factorial study.</p>
<p><span class="Bold">Alogliptin</span></p>
<p>Single-dose administration of alogliptin to healthy subjects resulted in a peak inhibition of DPP-4 within two to three hours after dosing. The peak inhibition of DPP-4 exceeded 93% across doses of 12.5 mg to 800 mg. Inhibition of DPP-4 remained above 80% at 24 hours for doses greater than or equal to 25 mg. Peak and total exposure over 24 hours to active GLP-1 were three- to four-fold greater with alogliptin (at doses of 25 to 200 mg) than placebo. In a 16-week, double-blind, placebo-controlled study alogliptin 25 mg demonstrated decreases in postprandial glucagon while increasing postprandial active GLP-1 levels compared to placebo over an eight-hour period following a standardized meal. It is unclear how these findings relate to changes in overall glycemic control in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. In this study, alogliptin 25 mg alone demonstrated decreases in two-hour postprandial glucose compared to placebo (-30 mg/dL versus 17.3 mg/dL respectively).</p>
<p>Multiple-dose administration of alogliptin to patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> also resulted in a peak inhibition of DPP-4 within one to two hours and exceeded 93% across all doses (25 mg, 100 mg and 400 mg) after a single dose and after 14 days of once-daily dosing). At these doses of alogliptin, inhibition of DPP-4 remained above 81% at 24 hours after 14 days of dosing.</p>
<p><span class="Bold">Pioglitazone</span></p>
<p>Clinical studies demonstrate that pioglitazone improves insulin sensitivity in insulin-resistant patients. Pioglitazone enhances cellular responsiveness to insulin, increases insulin-dependent glucose disposal, and improves hepatic sensitivity to insulin. In patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, the decreased <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span> produced by pioglitazone results in lower plasma glucose concentrations, lower plasma insulin concentrations and lower A1C values. In controlled clinical trials, pioglitazone had an additive effect on glycemic control when used in combination with a sulfonylurea, metformin or insulin <span class="Italics">[see <a href="#i4i_clinical_studies_ID_s14">Clinical Studies (14)</a>]</span>. Patients with lipid abnormalities were included in clinical trials with pioglitazone. Overall, patients treated with pioglitazone had mean decreases in serum triglycerides, mean increases in HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and no consistent mean changes in LDL and total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. There is no conclusive evidence of macrovascular benefit with pioglitazone or any other antidiabetic medication <span class="Italics">[see <a href="#ID_f568e9df-d5a6-4bd5-a82f-0347c427bd0c">Warnings and Precautions (5.11)</a> and <a href="#i4i_section_ID_s6.1">Adverse Reactions (6.1)</a>]</span>.</p>
<p>In a 26-week, placebo-controlled, dose-ranging monotherapy study, mean serum triglycerides decreased in the pioglitazone 15 mg, 30 mg and 45 mg dose groups compared to a mean increase in the placebo group. Mean HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> increased to a greater extent in patients treated with pioglitazone than in the placebo-treated patients. There were no consistent differences for LDL and total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in patients treated with pioglitazone compared to placebo <span class="Italics">(Table 7)</span>.</p>
<table width="100%">
<col width="46%">
<col width="10%">
<col width="14%">
<col width="14%">
<col width="14%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Adjusted for baseline, pooled center and pooled center by treatment interaction</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>p&lt;0.05 versus placebo</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="5" valign="top"><p class="First"><span class="Bold">Table 7. Lipids in a 26-Week, Placebo-Controlled, Monotherapy, Dose-Ranging Study</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Pioglitazone</span><br><span class="Bold">15 mg</span><br><span class="Bold">Once Daily</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Pioglitazone</span><br><span class="Bold">30 mg</span><br><span class="Bold">Once Daily</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Pioglitazone</span><br><span class="Bold">45 mg</span><br><span class="Bold">Once Daily</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Triglycerides (mg/dL)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=79</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=79</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=84</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=77</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">263</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">284</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">261</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">260</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Percent change from baseline (adjusted mean<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4.8%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-9%<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-9.6%<a href="#footnote-5" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-9.3%<a href="#footnote-5" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (mg/dL)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=79</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=79</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=83</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=77</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">42</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">40</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">41</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">41</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Percent change from baseline (adjusted mean<a href="#footnote-4" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.1%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">14.1%<a href="#footnote-5" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">12.2%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">19.1%<a href="#footnote-5" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (mg/dL)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=65</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=63</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=74</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=62</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">139</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">132</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">136</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">127</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Percent change from baseline (adjusted mean<a href="#footnote-4" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4.8%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">7.2%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5.2%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (mg/dL)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=79</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=79</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=84</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=77</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">225</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">220</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">223</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">214</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Percent change from baseline (adjusted mean<a href="#footnote-4" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4.4%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4.6%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">3.3%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6.4%</p></td>
</tr>
</tbody>
</table>
<p>In the two other monotherapy studies (16 weeks and 24 weeks) and in combination therapy studies with sulfonylurea (16 weeks and 24 weeks), metformin (16 weeks and 24 weeks) or insulin (16 weeks and 24 weeks), the lipid results were generally consistent with the data above.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_ID_s12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold">Absorption and Bioavailability</span></p>
<p><span class="Bold"><span class="Italics">Alogliptin and Pioglitazone</span></span></p>
<p>In bioequivalence studies of OSENI, the AUC and maximum concentration (C<span class="Sub">max</span>) of both the alogliptin and the pioglitazone component following a single dose of the combination tablet (12.5 mg/15 mg or 25 mg/45 mg) were bioequivalent to alogliptin (12.5 mg or 25 mg) concomitantly administered with pioglitazone (15 mg or 45 mg respectively) tablets under fasted conditions in healthy subjects.</p>
<p>Administration of OSENI 25 mg/45 mg with food resulted in no significant change in overall exposure of alogliptin or pioglitazone. OSENI may therefore be administered with or without food.</p>
<p><span class="Bold"><span class="Italics">Alogliptin</span></span></p>
<p>The absolute bioavailability of alogliptin is approximately 100%. Administration of alogliptin with a high-fat meal results in no significant change in total and peak exposure to alogliptin. Alogliptin may therefore be administered with or without food.</p>
<p><span class="Bold"><span class="Italics">Pioglitazone</span></span></p>
<p>Following oral administration of pioglitazone hydrochloride, peak concentrations of pioglitazone were observed within two hours. Food slightly delays the time to peak serum concentration (T<span class="Sub">max</span>) to three to four hours but does not alter the extent of absorption (AUC).</p>
<p><span class="Bold">Distribution</span></p>
<p><span class="Bold"><span class="Italics">Alogliptin</span></span></p>
<p>Following a single, 12.5 mg intravenous infusion of alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L, indicating that the drug is well distributed into tissues.</p>
<p>Alogliptin is 20% bound to plasma proteins.</p>
<p><span class="Bold"><span class="Italics">Pioglitazone</span></span></p>
<p>The mean apparent V<span class="Sub">d</span>/F of pioglitazone following single-dose administration is 0.63 ± 0.41 (mean ± SD) L/kg of body weight. Pioglitazone is extensively protein bound (&gt;99%) in human serum, principally to serum albumin. Pioglitazone also binds to other serum proteins, but with lower affinity. Metabolites M-III and M-IV also are extensively bound (&gt;98%) to serum albumin.</p>
<p><span class="Bold">Metabolism</span></p>
<p><span class="Bold"><span class="Italics">Alogliptin</span></span></p>
<p>Alogliptin does not undergo extensive metabolism, and 60% to 71% of the dose is excreted as unchanged drug in the urine.</p>
<p>Two minor metabolites were detected following administration of an oral dose of [<span class="Sup">14</span>C] alogliptin, <span class="Italics">N</span>-demethylated, M-I (&lt;1% of the parent compound), and <span class="Italics">N</span>-acetylated alogliptin, M-II (&lt;6% of the parent compound). M-I is an active metabolite and is an inhibitor of DPP-4 similar to the parent molecule; M-II does not display any inhibitory activity toward DPP-4 or other DPP-related enzymes. <span class="Italics">In vitro </span>data indicate that, CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin.</p>
<p>Alogliptin exists predominantly as the (<span class="Italics">R</span>)-enantiomer (&gt;99%) and undergoes little or no chiral conversion <span class="Italics">in vivo</span> to the (<span class="Italics">S</span>)-enantiomer. The (<span class="Italics">S</span>)-enantiomer is not detectable at the 25 mg dose.</p>
<p><span class="Bold"><span class="Italics">Pioglitazone</span></span></p>
<p>Pioglitazone is extensively metabolized by hydroxylation and oxidation; the metabolites also partly convert to glucuronide or sulfate conjugates. Metabolites M-III and M-IV are the major circulating active metabolites in humans. Following once-daily administration of pioglitazone, steady-state serum concentrations of both pioglitazone and its major active metabolites, M-III (keto derivative of pioglitazone) and M-IV (hydroxyl derivative of pioglitazone), are achieved within seven days. At steady-state, M-III and M-IV reach serum concentrations equal to or greater than that of pioglitazone. At steady-state, in both healthy volunteers and patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, pioglitazone comprises approximately 30% to 50% of the peak total pioglitazone serum concentrations (pioglitazone plus active metabolites) and 20% to 25% of the total AUC.</p>
<p>Maximum serum concentration (C<span class="Sub">max</span>), AUC and trough serum concentrations (C<span class="Sub">min</span>) for pioglitazone and M-III and M-IV, increased proportionally with administered doses of 15 mg and 30 mg per day.</p>
<p><span class="Italics">In vitro</span> data demonstrate that multiple CYP isoforms are involved in the metabolism of pioglitazone. The cytochrome P450 isoforms involved are CYP2C8 and, to a lesser degree, CYP3A4 with additional contributions from a variety of other isoforms, including the mainly extrahepatic CYP1A1. <span class="Italics">In vivo</span> studies of pioglitazone in combination with gemfibrozil, a strong CYP2C8 inhibitor, showed that pioglitazone is a CYP2C8 substrate <span class="Italics">[see <a href="#i4i_section_ID_s2.5">Dosage and Administration (2.3)</a> and <a href="#i4i_interactions_ID_s7">Drug Interactions (7)</a>]</span>. Urinary 6β-hydroxycortisol/cortisol ratios measured in patients treated with pioglitazone showed that pioglitazone is not a strong CYP3A4 enzyme inducer.</p>
<p><span class="Bold">Excretion and Elimination</span></p>
<p><span class="Bold"><span class="Italics">Alogliptin</span></span></p>
<p>The primary route of elimination of [<span class="Sup">14</span>C] alogliptin derived radioactivity occurred via renal excretion (76%), with 13% recovered in the feces, achieving a total recovery of 89% of the administered radioactive dose. The renal clearance of alogliptin (9.6 L/hr) indicates some active renal tubular secretion and systematic clearance was 14.0 L/hr.</p>
<p><span class="Bold"><span class="Italics">Pioglitazone</span></span></p>
<p>Following oral administration, approximately 15% to 30% of the pioglitazone dose is recovered in the urine. Renal elimination of pioglitazone is negligible, and the drug is excreted primarily as metabolites and their conjugates. It is presumed that most of the oral dose is excreted into the bile either unchanged or as metabolites and eliminated in the feces.</p>
<p>The mean serum half-life of pioglitazone and its metabolites (M-III and M-IV) range from three to seven hours and 16 to 24 hours, respectively. Pioglitazone has an apparent clearance, CL/F, calculated to be 5 to 7 L/hr.</p>
<p><span class="Bold">Special Populations</span></p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p><span class="Bold"><span class="Underline">Alogliptin</span></span></p>
<p>A single-dose, open-label study was conducted to evaluate the pharmacokinetics of alogliptin 50 mg in patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span> compared with healthy subjects. In patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance [CrCl] ≥60 to &lt;90 mL/min), an approximate 1.2-fold increase in plasma AUC of alogliptin was observed. Because increases of this magnitude are not considered clinically relevant, dose adjustment for patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not recommended.</p>
<p>In patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl ≥30 to &lt;60 mL/min), an approximate two-fold increase in plasma AUC of alogliptin was observed. To maintain similar systemic exposures of OSENI to those with normal renal function, the recommended dose of OSENI is 12.5 mg/15 mg, 12.5 mg/30 mg or 12.5 mg/45 mg once daily in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>In patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl ≥15 to &lt;30 mL/min) and ESRD (CrCl &lt;15 mL/min or requiring dialysis), approximate three- and four-fold increases in plasma AUC of alogliptin were observed, respectively. Dialysis removed approximately 7% of the drug during a three-hour dialysis session. OSENI is not recommended for patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or ESRD. Coadministration of pioglitazone and alogliptin 6.25 mg once daily based on individual requirements may be considered in these patients.</p>
<p><span class="Bold"><span class="Underline">Pioglitazone </span></span></p>
<p>The serum elimination half-life of pioglitazone, M-III and M-IV remains unchanged in patients with moderate (creatinine clearance 30 to 50 mL/min) to severe (creatinine clearance &lt;30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> when compared to subjects with normal renal function. Therefore no dose adjustment in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is required.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></p>
<p><span class="Bold"><span class="Underline">Alogliptin</span></span></p>
<p>Total exposure to alogliptin was approximately 10% lower and peak exposure was approximately 8% lower in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Grade B) compared to healthy subjects. The magnitude of these reductions is not considered to be clinically meaningful. Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Grade C) have not been studied. Use caution when administering OSENI to patients with liver disease <span class="Italics">[see <a href="#ID_eb87414d-9583-48e9-a91a-abf8c14c194c">Use in Specific Populations (8.6)</a> and <a href="#i4i_section_ID_s5.4">Warnings and Precautions (5.4)</a>]</span>.</p>
<p><span class="Bold"><span class="Underline">Pioglitazone </span></span></p>
<p>Compared with healthy controls, subjects with impaired hepatic function (Child-Pugh Grade B and C) have an approximate 45% reduction in pioglitazone and total pioglitazone (pioglitazone, M-III and M-IV) mean peak concentrations but no change in the mean AUC values. Therefore, no dose adjustment in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is required.</p>
<p>There are postmarketing reports of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> with pioglitazone and clinical trials have generally excluded patients with serum ALT &gt;2.5 times the upper limit of the reference range. Use caution in patients with liver disease <span class="Italics">[see <a href="#i4i_section_ID_s5.4">Warnings and Precautions (5.4)</a>].</span></p>
<p><span class="Bold"><span class="Italics">Gender</span></span></p>
<p><span class="Bold"><span class="Underline">Alogliptin</span></span></p>
<p>No dose adjustment is necessary based on gender. Gender did not have any clinically meaningful effect on the pharmacokinetics of alogliptin.</p>
<p><span class="Bold"><span class="Underline">Pioglitazone </span></span></p>
<p>The mean C<span class="Sub">max</span> and AUC values of pioglitazone were increased 20% to 60% in women compared to men. In controlled clinical trials, A1C decreases from baseline were generally greater for females than for males (average mean difference in A1C 0.5%). Because therapy should be individualized for each patient to achieve glycemic control, no dose adjustment is recommended based on gender alone.</p>
<p><span class="Bold"><span class="Italics">Geriatric</span></span></p>
<p><span class="Bold"><span class="Underline">Alogliptin</span></span></p>
<p>No dose adjustment is necessary based on age. Age did not have any clinically meaningful effect on the pharmacokinetics of alogliptin.</p>
<p><span class="Bold"><span class="Underline">Pioglitazone </span></span></p>
<p>In healthy elderly subjects, peak serum concentrations of pioglitazone and total pioglitazone are not significantly different, but AUC values are approximately 21% higher than those achieved in younger subjects. The mean terminal half-life values of pioglitazone were also longer in elderly subjects (about 10 hours) as compared to younger subjects (about seven hours). These changes were not of a magnitude that would be considered clinically relevant.</p>
<p><span class="Bold"><span class="Italics">Pediatrics</span></span></p>
<p><span class="Bold"><span class="Underline">Alogliptin</span></span></p>
<p>Studies characterizing the pharmacokinetics of alogliptin in pediatric patients have not been performed.</p>
<p><span class="Bold"><span class="Underline">Pioglitazone </span></span></p>
<p>Safety and efficacy of pioglitazone in pediatric patients have not been established. Pioglitazone is not recommended for use in pediatric patients <span class="Italics">[see <a href="#i4i_pediatric_use_ID_s8.4">Use in Specific Populations (8.4)</a>]</span>.</p>
<p><span class="Bold"><span class="Italics">Race and Ethnicity</span></span></p>
<p><span class="Bold"><span class="Underline">Alogliptin</span></span></p>
<p>No dose adjustment is necessary based on race. Race (White, Black and Asian) did not have any clinically meaningful effect on the pharmacokinetics of alogliptin.</p>
<p><span class="Bold"><span class="Underline">Pioglitazone </span></span></p>
<p>Pharmacokinetic data among various ethnic groups are not available.</p>
<p><span class="Bold">Drug Interactions</span></p>
<p>Coadministration of alogliptin 25 mg once daily with a CYP2C8 substrate, pioglitazone 45 mg once daily for 12 days had no clinically meaningful effects on the pharmacokinetics of pioglitazone and its active metabolites.</p>
<p>Specific pharmacokinetic drug interaction studies with OSENI have not been performed, although such studies have been conducted with the individual components of OSENI (alogliptin and pioglitazone).</p>
<p><span class="Bold"><span class="Italics">Alogliptin</span></span></p>
<p><span class="Bold"><span class="Underline">In Vitro Assessment of Drug Interactions</span></span></p>
<p><span class="Italics">In vitro</span> studies indicate that alogliptin is neither an inducer of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4, nor an inhibitor of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP2D6 at clinically relevant concentrations.</p>
<p><span class="Bold">In Vivo Assessment of Drug Interactions</span></p>
<p><span class="Bold"><span class="Italics"><span class="Underline">Effects of Alogliptin on the Pharmacokinetics of Other Drugs</span></span></span></p>
<p>In clinical studies, alogliptin did not meaningfully increase the systemic exposure to the following drugs that are metabolized by CYP isozymes or excreted unchanged in urine (<span class="Italics">Figure 1</span>). No dose adjustment of alogliptin is recommended based on results of the described pharmacokinetic studies.</p>
<p><span class="Bold">Figure 1. Effect of Alogliptin on the Pharmacokinetic Exposure to Other Drugs</span></p>
<div class="Figure">
<a name="id7560320"></a><img alt="Figure1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55&amp;name=95b44edb-bd6f-471b-a1c7-44694551ecae-03.jpg">
</div>
<p>*Warfarin was given once daily at a stable dose in the range of 1 mg to 10 mg. Alogliptin had no significant effect on the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT) or International Normalized Ratio (INR).</p>
<p>**Caffeine (1A2 substrate), tolbutamide (2C9 substrate), dextromethorphan (2D6 substrate), midazolam (3A4 substrate) and fexofenadine (P-gp substrate) were administered as a cocktail.</p>
<p><span class="Bold"><span class="Italics"><span class="Underline">Effects of Other Drugs on the Pharmacokinetics of Alogliptin</span></span></span></p>
<p>There are no clinically meaningful changes in the pharmacokinetics of alogliptin when alogliptin is administered concomitantly with the drugs described below <span class="Italics">(Figure 2).</span></p>
<p><span class="Bold">Figure 2. Effect of Other Drugs on the Pharmacokinetic Exposure of Alogliptin</span></p>
<div class="Figure">
<a name="id90751169"></a><img alt="Figure2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55&amp;name=95b44edb-bd6f-471b-a1c7-44694551ecae-04.jpg">
</div>
<p><span class="Bold">Pioglitazone</span></p>
<table width="100%">
<col width="17%">
<col width="42%">
<col width="13%">
<col width="7%">
<col width="13%">
<col width="8%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Daily for seven days unless otherwise noted</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>% change (with/without coadministered drug and no change=0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>Pioglitazone had no clinically significant effect on <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="6" valign="middle"><p class="First"><span class="Bold">Table 8. Effect of Pioglitazone Coadministration on Systemic Exposure of Other Drugs</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="5" valign="middle"><p class="First"><span class="Bold">Coadministered Drug</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Pioglitazone Dosage</span><br><span class="Bold">Regimen (mg)</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Name and Dose Regimens</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First"><span class="Bold">Change in AUC</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First"><span class="Bold">Change in C<span class="Sub">max</span></span><a href="#footnote-7" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="3" valign="middle"><p class="First">45 mg<br>(N=12)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Warfarin</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2" valign="middle"><p class="First">Daily loading then maintenance doses based PT and INR values<br>Quick's Value=35 ± 5%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">R-Warfarin</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↓3%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">R-Warfarin</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↓2%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">S-Warfarin</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↓1%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">S-Warfarin</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↑1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="middle"><p class="First">45 mg<br>(N=12)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Digoxin</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">0.200 mg twice daily (loading dose) then<br>0.250 mg daily (maintenance dose, 7 days)</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↑15%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↑17%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="3" valign="middle"><p class="First">45 mg daily for 21 days<br>(N=35)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Oral Contraceptive</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2" valign="middle"><p class="First">[Ethinyl Estradiol (EE) 0.035 mg plus<br>Norethindrone (NE) 1 mg] for 21 days</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">EE</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↓11%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">EE</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↓13%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">NE</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↑3%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">NE</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↓7%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="middle"><p class="First">45 mg<br>(N=23)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Fexofenadine</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">60 mg twice daily for 7 days</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↑30%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↑37%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="middle"><p class="First">45 mg<br>(N=14)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Glipizide</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">5 mg daily for 7 days</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↓3%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↓8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="middle"><p class="First">45 mg daily for 8 days<br>(N=16)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Metformin</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">1000 mg single dose on 8 days</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↓3%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↓5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="middle"><p class="First">45 mg<br>(N=21)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Midazolam</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">7.5 mg single dose on day 15</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↓26%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↓26%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="middle"><p class="First">45 mg<br>(N=24)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Ranitidine</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">150 mg twice daily for 7 days</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↑1%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↓1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="middle"><p class="First">45 mg daily for 4 days<br>(N=24)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Nifedipine ER</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">30 mg daily for 4 days</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↓13%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↓17%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="middle"><p class="First">45 mg<br>(N=25)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Atorvastatin Ca</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">80 mg daily for 7 days</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↓14%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↓23%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="middle"><p class="First">45 mg<br>(N=22)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Theophylline</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">400 mg twice daily for 7 days</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↑2%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↑5%</p></td>
</tr>
</tbody>
</table>
<table width="100%">
<col width="52%">
<col width="17%">
<col width="15%">
<col width="15%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Daily for seven days unless otherwise noted</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>Mean ratio (with/without coadministered drug and no change=one-fold) % change (with/without coadministered drug and no change=0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">‡</a></dt>
<dd>The half-life of pioglitazone increased from 6.5 hours to 15.1 hours in the presence of gemfibrozil <span class="Italics">[see Dosage and Administration (2.3) and Drug Interactions (7)]</span>
</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="4" valign="top"><p class="First"><span class="Bold">Table 9. Effect of Coadministered Drugs on Pioglitazone Systemic Exposure</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="top"><p class="First"><span class="Bold">Coadministered Drug and Dosage Regimen</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Pioglitazone</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Dose Regimen</span><br><span class="Bold">(mg)</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Change in AUC</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Change in C<span class="Sub">max</span></span><a href="#footnote-10" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">Gemfibrozil 600 mg<br>twice daily for 2 days<br>(N=12)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">30 mg<br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↑3.4-fold<a name="footnote-reference-11" href="#footnote-11" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↑6%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">Ketoconazole 200 mg<br>twice daily for 7 days<br>(N=28)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">45 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↑34%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↑14%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">Rifampin 600 mg<br>daily for 5 days<br>(N=10)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">30 mg<br>single dose</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↓54%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↓5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">Fexofenadine 60 mg<br>twice daily for 7 days<br>(N=23)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">45 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↑1%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">Ranitidine 150 mg<br>twice daily for 4 days<br>(N=23)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">45 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↓13%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↓16%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">Nifedipine ER 30 mg<br>daily for 7 days<br>(N = 23)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">45 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↑5%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↑4%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">Atorvastatin Ca 80 mg<br>daily for 7 days<br>(N=24)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">45 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↓24%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↓31%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">Theophylline 400 mg<br>twice daily for 7 days<br>(N=22)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">45 mg</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↓4%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↓2%</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_ID_s13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_ID_s13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Bold">Alogliptin and Pioglitazone</span></p>
<p>No carcinogenicity, mutagenicity or impairment of fertility studies have been conducted with OSENI. The following data are based on findings in studies performed with alogliptin or pioglitazone individually.</p>
<p><span class="Bold">Alogliptin</span></p>
<p>Rats were administered oral doses of 75, 400 and 800 mg/kg alogliptin for two years. No drug-related tumors were observed up to 75 mg/kg, or approximately 32 times the maximum recommended clinical dose of 25 mg, based on AUC exposure. At higher doses (approximately 308 times the maximum recommended clinical dose of 25 mg), a combination of thyroid C-cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas increased in male but not female rats. No drug-related tumors were observed in mice after administration of 50, 150 or 300 mg/kg alogliptin for two years, or up to approximately 51 times the maximum recommended clinical dose of 25 mg, based on AUC exposure.</p>
<p>Alogliptin was not mutagenic or clastogenic, with and without metabolic activation, in the Ames test with <span class="Italics">S. typhimurium</span> and <span class="Italics">E. coli</span> or the cytogenetic assay in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells. Alogliptin was negative in the <span class="Italics">in vivo</span> mouse micronucleus study.</p>
<p>In a fertility study in rats, alogliptin had no adverse effects on early embryonic development, mating or fertility at doses up to 500 mg/kg, or approximately 172 times the clinical dose based on plasma drug exposure (AUC).</p>
<p><span class="Bold">Pioglitazone</span></p>
<p>A two-year carcinogenicity study was conducted in male and female rats at oral doses up to 63 mg/kg (approximately 14 times the MRHD of 45 mg based on mg/m<span class="Sup">2</span>). Drug-induced tumors were not observed in any organ except for the urinary bladder. Benign and/or malignant transitional cell neoplasms were observed in male rats at 4 mg/kg and above (approximately equal to the MRHD based on mg/m<span class="Sup">2</span>). A two-year carcinogenicity study was conducted in male and female mice at oral doses up to 100 mg/kg (approximately 11 times the MRHD based on mg/m<span class="Sup">2</span>). No drug-induced tumors were observed in any organ.</p>
<p>Pioglitazone was not mutagenic in a battery of genetic toxicology studies, including the Ames bacterial assay, a mammalian cell forward gene mutation assay (CHO/HPRT and AS52/XPRT), an <span class="Italics">in vitro</span> cytogenetics assay using CHL cells, an unscheduled DNA synthesis assay and an <span class="Italics">in vivo</span> micronucleus assay.</p>
<p>No adverse effects upon fertility were observed in male and female rats at oral doses up to 40 mg/kg pioglitazone daily prior to and throughout mating and gestation (approximately nine times the MRHD based on mg/m<span class="Sup">2</span>).</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_ID_s13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First"><span class="Bold">Pioglitazone</span></p>
<p>Heart enlargement has been observed in mice (100 mg/kg), rats (4 mg/kg and above) and dogs (3 mg/kg) treated orally with pioglitazone (approximately 11, one, and two times the MRHD for mice, rats and dogs, respectively, based on mg/m<span class="Sup">2</span>). In a one-year rat study, drug-related early <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to apparent heart dysfunction occurred at an oral dose of 160 mg/kg (approximately 35 times the MRHD based on mg/m<span class="Sup">2</span>). Heart enlargement was seen in a 13-week study in monkeys at oral doses of 8.9 mg/kg and above (approximately four times the MRHD based on mg/m<span class="Sup">2</span>), but not in a 52-week study at oral doses up to 32 mg/kg (approximately 13 times the MRHD based on mg/m<span class="Sup">2</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_ID_s14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The coadministration of alogliptin and pioglitazone has been studied in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on either diet and exercise alone or on metformin alone.</p>
<p>There have been no clinical efficacy studies conducted with OSENI; however, bioequivalence of OSENI with coadministered alogliptin and pioglitazone tablets was demonstrated, and efficacy of the combination of alogliptin and pioglitazone has been demonstrated in four Phase 3 efficacy studies.</p>
<p>In patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, treatment with OSENI produced clinically meaningful and statistically significant improvements in A1C compared to either alogliptin or pioglitazone alone. As is typical for trials of agents to treat type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, the mean reduction in A1C with OSENI appears to be related to the degree of A1C elevation at baseline.</p>
<p><span class="Bold">Alogliptin and Pioglitazone Coadministration in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Inadequately Controlled on Diet and Exercise</span></p>
<p>In a 26-week, double-blind, active-controlled study, a total of 655 patients inadequately controlled on diet and exercise alone (mean baseline A1C = 8.8%) were randomized to receive alogliptin 25 mg alone, pioglitazone 30 mg alone, alogliptin 12.5 mg with pioglitazone 30 mg or alogliptin 25 mg with pioglitazone 30 mg once daily. Coadministration of alogliptin 25 mg with pioglitazone 30 mg resulted in statistically significant improvements from baseline in A1C and FPG compared to either alogliptin 25 mg alone or to pioglitazone 30 mg alone <span class="Italics">(Table 10)</span>. Coadministration of alogliptin 25 mg with pioglitazone 30 mg once daily resulted in statistically significant reductions in fasting plasma glucose (FPG) starting from Week 2 through Week 26 compared to either alogliptin 25 mg or pioglitazone 30 mg alone. A total of 3% of patients receiving alogliptin 25 mg coadministered with pioglitazone 30 mg, 11% of those receiving alogliptin 25 mg alone, and 6% of those receiving pioglitazone 30 mg alone required glycemic rescue.</p>
<p>Improvements in A1C were not affected by gender, age or baseline BMI.</p>
<p>The mean increase in body weight was similar between pioglitazone alone and alogliptin when coadministered with pioglitazone.</p>
<table width="100%">
<col width="49%">
<col width="11%">
<col width="13%">
<col width="27%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-12" href="#footnote-reference-12">*</a></dt>
<dd>Intent-to-treat population using last observation carried forward</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">†</a></dt>
<dd>Least squares means adjusted for treatment, geographic region and baseline value</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">‡</a></dt>
<dd>p&lt;0.01 compared to alogliptin 25 mg or pioglitazone 30 mg</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="4" valign="top"><p class="First"><span class="Bold">Table 10. Glycemic Parameters at Week 26 in a Coadministration Study of Alogliptin and Pioglitazone in Patients Inadequately Controlled on Diet and Exercise</span><a name="footnote-reference-12" href="#footnote-12" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Alogliptin</span><br><span class="Bold">25 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Pioglitazone</span><br><span class="Bold">30 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Alogliptin 25 mg + Pioglitazone 30 mg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">A1C (%)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=160</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=153</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=158</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Change from Baseline (adjusted mean<a name="footnote-reference-13" href="#footnote-13" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Difference from alogliptin 25 mg (adjusted mean<a href="#footnote-13" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.8<a name="footnote-reference-14" href="#footnote-14" class="Sup">‡</a> (-1, -0.5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Difference from pioglitazone 30 mg (adjusted mean<a href="#footnote-13" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.6<a href="#footnote-14" class="Sup">‡</a> (-0.8, -0.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">% of Patients (n/N) achieving A1C ≤ 7%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">24%<br>(40/164)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">34%<br>(55/163)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">63%<br>(103/164)<a href="#footnote-14" class="Sup">‡</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=162</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=157</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=162</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">189</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">189</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">185</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Change from Baseline (adjusted mean<a href="#footnote-13" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-26</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-37</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-50</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Difference from alogliptin 25 mg (adjusted mean<a href="#footnote-13" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-25<a href="#footnote-14" class="Sup">‡</a> (-34, -15)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Difference from pioglitazone 30 mg (adjusted mean<a href="#footnote-13" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-13<a href="#footnote-14" class="Sup">‡</a> (-22, -4)</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Alogliptin and Pioglitazone Coadministration in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Inadequately Controlled on Metformin Alone</span></p>
<p>In the second 26-week, double-blind, placebo-controlled study, a total of 1554 patients already on metformin (mean baseline A1C=8.5%) were randomized to one of 12 double-blind treatment groups: placebo; 12.5 mg or 25 mg of alogliptin alone; 15 mg, 30 mg or 45 mg of pioglitazone alone; or 12.5 mg or 25 mg of alogliptin in combination with 15 mg, 30 mg or 45 mg of pioglitazone. Patients were maintained on a stable dose of metformin (median dose=1700 mg) during the treatment period. Coadministration of alogliptin and pioglitazone provided statistically significant improvements in A1C and FPG compared to placebo, to alogliptin alone, or to pioglitazone alone when added to background metformin therapy <span class="Italics">(Table 11, Figure 3)</span>. A total of 4%, 5% or 2% of patients receiving alogliptin 25 mg with 15 mg, 30 mg or 45 mg pioglitazone, 33% of patients receiving placebo, 13% of patients receiving alogliptin 25 mg, and 10%, 15% or 9% of patients receiving pioglitazone 15 mg, 30 mg or 45 mg alone required glycemic rescue.</p>
<p>Improvements in A1C were not affected by gender, age or baseline BMI.</p>
<p>The mean increase in body weight was similar between pioglitazone alone and alogliptin when coadministered with pioglitazone.</p>
<table width="100%">
<col width="11%">
<col width="8%">
<col width="10%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="12%">
<tfoot><tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>Intent-to-treat population using last observation carried forward</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">†</a></dt>
<dd>Least squares means adjusted for treatment, geographic region, metformin dose and baseline value</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">‡</a></dt>
<dd>p≤0.01 when compared to pioglitazone and alogliptin alone</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="9" valign="top"><p class="First"><span class="Bold">Table 11. Glycemic Parameters at Week 26 for Alogliptin and Pioglitazone Alone and in Combination in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></span><a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Alogliptin</span><br><span class="Bold">25 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Pioglitazone</span><br><span class="Bold">15 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Pioglitazone</span><br><span class="Bold">30 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Pioglitazone</span><br><span class="Bold">45 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Alogliptin</span><br><span class="Bold">25 mg + Pioglitazone</span><br><span class="Bold">15 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Alogliptin</span><br><span class="Bold">25 mg + Pioglitazone</span><br><span class="Bold">30 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Alogliptin</span><br><span class="Bold">25 mg + Pioglitazone</span><br><span class="Bold">45 mg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">A1C (%)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=126</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=123</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=127</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=123</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=126</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=127</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=124</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=126</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Change from baseline (adjusted mean<a name="footnote-reference-16" href="#footnote-16" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1.3<a name="footnote-reference-17" href="#footnote-17" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1.4<a href="#footnote-17" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1.6<a href="#footnote-17" class="Sup">‡</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Difference from pioglitazone (adjusted mean<a href="#footnote-16" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.5<a href="#footnote-17" class="Sup">‡</a> (-0.7, -0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.5<a href="#footnote-17" class="Sup">‡</a> (-0.7,<br>-0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.6<a href="#footnote-17" class="Sup">‡</a> (-0.8,<br>-0.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Difference from alogliptin (adjusted mean<a href="#footnote-16" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.4<a href="#footnote-17" class="Sup">‡</a> (-0.6, -0.1)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.5<a href="#footnote-17" class="Sup">‡</a> (-0.7,<br>-0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.7<a href="#footnote-17" class="Sup">‡</a> (-0.9,<br>-0.5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Patients (%) achieving A1C ≤7%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6%<br>(8/129)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">27%<br>(35/129)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">26%<br>(33/129)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">30%<br>(38/129)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">36%<br>(47/129)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">55%<br>(71/130)<a href="#footnote-17" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">53%<br>(69/130)<a href="#footnote-17" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">60%<br>(78/130)<a href="#footnote-17" class="Sup">‡</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=129</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=126</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=127</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=125</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=129</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=130</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=126</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=127</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">177</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">184</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">177</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">175</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">181</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">179</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">179</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">178</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Change from baseline (adjusted mean<a href="#footnote-16" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-19</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-24</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-29</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-32</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-38<a href="#footnote-17" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-42<a href="#footnote-17" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-53<a href="#footnote-17" class="Sup">‡</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Difference from pioglitazone (adjusted mean<a href="#footnote-16" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-14<a href="#footnote-17" class="Sup">‡</a> (-24, -5)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-13<a href="#footnote-17" class="Sup">‡</a> (-23, -3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-20<a href="#footnote-17" class="Sup">‡</a> (-30,<br>-11)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Difference from alogliptin (adjusted mean<a href="#footnote-16" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-19<a href="#footnote-17" class="Sup">‡</a> (-29, -10)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-23<a href="#footnote-17" class="Sup">‡</a> (-33, -13)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-34<a href="#footnote-17" class="Sup">‡</a> (-44,<br>-24)</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 3. Change from Baseline in A1C at Week 26 with Alogliptin and Pioglitazone Alone and Alogliptin in Combination with Pioglitazone when Added to Metformin</span></p>
<div class="Figure">
<a name="id7580006"></a><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55&amp;name=95b44edb-bd6f-471b-a1c7-44694551ecae-05.jpg">
</div>
<p><span class="Bold">Alogliptin Add-On Therapy in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Inadequately Controlled on Metformin in Combination with Pioglitazone </span></p>
<p>In a 52-week, active-comparator study, a total of 803 patients inadequately controlled (mean baseline A1C = 8.2%) on a current regimen of pioglitazone 30 mg and metformin at least 1500 mg per day or at the maximum tolerated dose were randomized to either receive the addition of alogliptin 25 mg or the titration of pioglitazone 30 mg to 45 mg following a four-week, single-blind, placebo run-in period. Patients were maintained on a stable dose of metformin (median dose = 1700 mg). Patients who failed to meet prespecified hyperglycemic goals during the 52-week treatment period received glycemic rescue therapy.</p>
<p>In combination with pioglitazone and metformin, alogliptin 25 mg was shown to be statistically superior in lowering A1C and FPG compared with the titration of pioglitazone from 30 mg to 45 mg at Week 26 and Week 52 <span class="Italics">(Table 12, results shown only for Week 52)</span>. A total of 11% of patients who were receiving alogliptin 25 mg in combination with pioglitazone 30 mg and metformin and 22% of patients receiving a dose titration of pioglitazone from 30 mg to 45 mg in combination with metformin required glycemic rescue.</p>
<p>Improvements in A1C were not affected by gender, age, race or baseline BMI. The mean increase in body weight was similar in both treatment arms. Lipid effects were neutral.</p>
<table width="100%">
<col width="48%">
<col width="30%">
<col width="22%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-18" href="#footnote-reference-18">*</a></dt>
<dd>Intent-to-treat population using last observation on study</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">†</a></dt>
<dd>Least squares means adjusted for treatment, baseline value, geographic region and baseline metformin dose</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">‡</a></dt>
<dd>Noninferior and statistically superior to metformin plus pioglitazone at the 0.025 one-sided significance level</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">§</a></dt>
<dd>p&lt;0.001 compared to pioglitazone 45 mg + metformin</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First"><span class="Bold">Table 12. Glycemic Parameters at Week 52 in an Active-Controlled Study of Alogliptin as Add-On Combination Therapy to Metformin and Pioglitazone</span><a name="footnote-reference-18" href="#footnote-18" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Bold">Alogliptin 25 mg </span></p>
<p><span class="Bold">+ Pioglitazone 30 mg </span></p>
<p><span class="Bold">+ Metformin</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Bold">Pioglitazone 45 mg </span></p>
<p><span class="Bold">+ Metformin</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">A1C (%)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=397</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=394</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Change from Baseline (adjusted mean<a name="footnote-reference-19" href="#footnote-19" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Difference from Pioglitazone 45 mg + Metformin (adjusted mean<a href="#footnote-19" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.4<a name="footnote-reference-20" href="#footnote-20" class="Sup">‡</a> (-0.5, -0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">% of Patients (n/N) achieving A1C ≤7%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">33% (134/404)<a name="footnote-reference-21" href="#footnote-21" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">21% (85/399)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=399</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=396</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">162</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">162</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Change from Baseline (adjusted mean<a href="#footnote-19" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-15</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-4</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Difference from Pioglitazone 45 mg + Metformin (adjusted mean<a href="#footnote-19" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-11<a href="#footnote-21" class="Sup">§</a> (-16, -6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Alogliptin Add-On Therapy to a Thiazolidinedione</span></p>
<p>A 26-week, placebo-controlled study, was conducted to evaluate the efficacy and safety of alogliptin as add-on therapy to pioglitazone in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. A total of 493 patients inadequately controlled on a thiazolidinedione alone or in combination with metformin or a sulfonylurea (mean baseline A1C = 8%) were randomized to receive alogliptin 12.5 mg, alogliptin 25 mg or placebo. Patients were maintained on a stable dose of pioglitazone (median dose = 30 mg) during the treatment period and those who were also previously treated on metformin (median dose = 2000 mg) or sulfonylurea (median dose = 10 mg) prior to randomization were maintained on the combination therapy during the treatment period. All patients entered into a four-week, single-blind, placebo run-in period prior to randomization. Following randomization, all patients continued to receive instruction on diet and exercise. Patients who failed to meet prespecified hyperglycemic goals during the 26-week treatment period received glycemic rescue.</p>
<p>The addition of alogliptin 25 mg once daily to pioglitazone therapy resulted in significant improvements from baseline in A1C and FPG at Week 26 when compared to the addition of placebo <span class="Italics">(Table 13)</span>. A total of 9% of patients who were receiving alogliptin 25 mg and 12% of patients receiving placebo required glycemic rescue.</p>
<p>The improvement in A1C was not affected by gender, age, baseline BMI or baseline pioglitazone dose. The mean increase in body weight was similar between alogliptin and placebo when given in combination with pioglitazone. Lipid effects were neutral.</p>
<table width="100%">
<col width="53%">
<col width="23%">
<col width="23%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-22" href="#footnote-reference-22">*</a></dt>
<dd>Intent-to-treat population using last observation on study</dd>
<dt><a name="footnote-23" href="#footnote-reference-23">†</a></dt>
<dd>Least squares means adjusted for treatment, baseline value, geographic region, baseline treatment regimen (pioglitazone, pioglitazone plus metformin or pioglitazone plus sulfonylurea) and baseline pioglitazone dose</dd>
<dt><a name="footnote-24" href="#footnote-reference-24">‡</a></dt>
<dd>p&lt;0.01 compared to placebo</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First"><span class="Bold">Table 13. Glycemic Parameters at Week 26 in a Placebo-Controlled Study of Alogliptin as Add-On Therapy to Pioglitazone</span><a name="footnote-reference-22" href="#footnote-22" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Bold">Alogliptin 25 mg </span></p>
<p><span class="Bold">+ Pioglitazone</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Bold">Placebo </span></p>
<p><span class="Bold">+ Pioglitazone</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">A1C (%)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=195</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=95</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Change from baseline (adjusted mean<a name="footnote-reference-23" href="#footnote-23" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Difference from placebo (adjusted mean<a href="#footnote-23" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.6<a name="footnote-reference-24" href="#footnote-24" class="Sup">‡</a> (-0.8, -0.4)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">% of patients (n/N) achieving A1C ≤7%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">49%<br>(98/199)<a href="#footnote-24" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">34%<br>(33/97)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=197</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=97</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">170</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">172</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Change from baseline (adjusted mean<a href="#footnote-23" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-20</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-6</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Difference from placebo (adjusted mean<a href="#footnote-23" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-14<a href="#footnote-24" class="Sup">‡</a> (-23, -5)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_s16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">OSENI tablets are available in the following strengths and packages:</p>
<p>25 mg/15 mg tablet: yellow, round, biconvex and film-coated with both "A/P" and "25/15" printed on one side, available in:</p>
<table width="50%">
<col width="28%">
<col width="30%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First">NDC 64764-251-03</p></td>
<td class="Toprule" valign="top"><p class="First">Bottles of 30 tablets</p></td>
</tr>
<tr>
<td valign="top"><p class="First">NDC 64764-251-04</p></td>
<td valign="top"><p class="First">Bottles of 90 tablets</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">NDC 64764-251-05</p></td>
<td class="Botrule" valign="top"><p class="First">Bottles of 500 tablets</p></td>
</tr>
</tbody>
</table>
<p>25 mg/30 mg tablet: peach, round, biconvex and film-coated with both "A/P" and "25/30" printed on one side, available in:</p>
<table width="50%">
<col width="28%">
<col width="30%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First">NDC 64764-253-03</p></td>
<td class="Toprule" valign="top"><p class="First">Bottles of 30 tablets</p></td>
</tr>
<tr>
<td valign="top"><p class="First">NDC 64764-253-04 </p></td>
<td valign="top"><p class="First">Bottles of 90 tablets</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">NDC 64764-253-05</p></td>
<td class="Botrule" valign="top"><p class="First">Bottles of 500 tablets</p></td>
</tr>
</tbody>
</table>
<p>25 mg/45 mg tablet: red, round, biconvex, film-coated and with both "A/P" and "25/45" printed on one side, available in:</p>
<table width="50%">
<col width="28%">
<col width="30%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First">NDC 64764-254-03</p></td>
<td class="Toprule" valign="top"><p class="First">Bottles of 30 tablets</p></td>
</tr>
<tr>
<td valign="top"><p class="First">NDC 64764-254-04</p></td>
<td valign="top"><p class="First">Bottles of 90 tablets</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">NDC 64764-254-05</p></td>
<td class="Botrule" valign="top"><p class="First">Bottles of 500 tablets</p></td>
</tr>
</tbody>
</table>
<p>12.5 mg/15 mg tablet: <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, round, biconvex and film-coated with both "A/P" and "12.5/15" printed on one side, available in:</p>
<table width="50%">
<col width="28%">
<col width="30%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First">NDC 64764-121-03</p></td>
<td class="Toprule" valign="top"><p class="First">Bottles of 30 tablets</p></td>
</tr>
<tr>
<td valign="top"><p class="First">NDC 64764-121-04</p></td>
<td valign="top"><p class="First">Bottles of 90 tablets</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">NDC 64764-121-05</p></td>
<td class="Botrule" valign="top"><p class="First">Bottles of 500 tablets</p></td>
</tr>
</tbody>
</table>
<p>12.5 mg/30 mg tablet: <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> peach, round, biconvex and film-coated with both "A/P" and "12.5/30" printed on one side, available in:</p>
<table width="50%">
<col width="28%">
<col width="30%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First">NDC 64764-123-03</p></td>
<td class="Toprule" valign="top"><p class="First">Bottles of 30 tablets</p></td>
</tr>
<tr>
<td valign="top"><p class="First">NDC 64764-123-04</p></td>
<td valign="top"><p class="First">Bottles of 90 tablets</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">NDC 64764-123-05</p></td>
<td class="Botrule" valign="top"><p class="First">Bottles of 500 tablets</p></td>
</tr>
</tbody>
</table>
<p>12.5 mg/45 mg tablet: <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> red, round, biconvex and film-coated with both "A/P" and "12.5/45" printed on one side, available in:</p>
<table width="50%">
<col width="28%">
<col width="30%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First">NDC 64764-124-03</p></td>
<td class="Toprule" valign="top"><p class="First">Bottles of 30 tablets</p></td>
</tr>
<tr>
<td valign="top"><p class="First">NDC 64764-124-04</p></td>
<td valign="top"><p class="First">Bottles of 90 tablets</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">NDC 64764-124-05</p></td>
<td class="Botrule" valign="top"><p class="First">Bottles of 500 tablets</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_dcc5af3d-61b8-462c-ae81-2fc65cdc2923"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p>Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Keep container tightly closed and protect from moisture and humidity.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_ID_s17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-Approved Patient Labeling (Medication Guide).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Instructions</h2>
<p class="First">Inform patients of the potential risks and benefits of OSENI.</p>
<p>Patients who experience an unusually rapid increase in weight or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or who develop <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or other symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> while on OSENI should immediately report these symptoms to their physician.</p>
<p>Patients should be informed that <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span> has been reported during use of alogliptin. Patients should be informed that persistent, severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, sometimes radiating to the back, which may or may not be accompanied by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, is the hallmark symptom of <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>. Patients should be instructed to promptly discontinue OSENI and contact their physician if persistent severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> occurs.</p>
<p>Patients should be informed that <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> have been reported during use of alogliptin and pioglitazone. If symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue and throat that may cause difficulty in breathing or swallowing) occur, patients should be instructed to discontinue OSENI and seek medical advice promptly.</p>
<p>Patients should be informed that postmarketing reports of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, sometimes fatal, have been reported during use of alogliptin and pioglitazone. If signs or symptoms of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> occur (e.g., unexplained <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> or dark urine), patients should be instructed to discontinue OSENI and seek medical advice promptly. </p>
<p>Tell patients to promptly report any sign of <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">macroscopic hematuria</span> or other symptoms such as <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span> or <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">urinary urgency</span> that develop or increase during treatment, as these may be due to <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>.</p>
<p>Inform patients that <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> can occur, particularly when an insulin secretagogue or insulin is used in combination with OSENI. Explain the risks, symptoms and appropriate management of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
<p>Therapy with thiazolidinediones, including pioglitazone, which is one of the active components of OSENI, may result in ovulation in some premenopausal anovulatory women. As a result, these patients may be at an increased risk for pregnancy while taking OSENI. Therefore, adequate contraception should be recommended for all premenopausal women who are prescribed OSENI.</p>
<p>Inform patients that severe and disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> may occur with this class of drugs. The time to onset of symptoms can range from one day to years. Instruct patients to seek medical advice if severe <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> occurs.</p>
<p>Instruct patients to take OSENI only as prescribed daily. OSENI can be taken with or without meals. If a dose is missed, advise patients not to double their next dose.</p>
<p>Patients should be informed that the tablets must never be split.</p>
<p>Instruct patients to read the Medication Guide before starting OSENI therapy and to reread each time the prescription is refilled. Instruct patients to inform their healthcare provider if an unusual symptom develops or if a symptom persists or worsens.</p>
<p>Revised: August 2015<br>ALP008 R4</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_ID_med"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">OSENI (OH-senn-ee)</span><br><span class="Bold">(alogliptin and pioglitazone)</span><br><span class="Bold">tablets</span></p>
<p>Read this Medication Guide carefully before you start taking OSENI and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. If you have any questions about OSENI, ask your doctor or pharmacist.</p>
<p><span class="Bold">What is the most important information I should know about OSENI?</span></p>
<p><span class="Bold">OSENI can cause serious side effects, including:</span></p>
<dl>
<dt>1.</dt>
<dd>
<span class="Bold">New or worse <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>:</span> Pioglitazone, one of the medicines in OSENI, can cause your body to keep extra fluid (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>), which leads to <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>) and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. Extra body fluid can make some heart problems worse or lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> means your heart does not pump blood well enough.<dl>
<dt>•</dt>
<dd>Do not take OSENI if you have severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</dd>
<dt>•</dt>
<dd>If you have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with symptoms (such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>), even if these symptoms are not severe, OSENI may not be right for you.</dd>
</dl>
</dd>
<dt> </dt>
<dd>
<span class="Bold">Call your doctor right away if you have any of the following:</span><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, especially in the ankles or legs</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing, especially when you lie down</dd>
<dt>•</dt>
<dd>an unusually fast increase in weight</dd>
<dt>•</dt>
<dd>unusual <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></dd>
</dl>
</dd>
<dt>2.</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> of the pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>):</span> Alogliptin, one of the medicines in OSENI, may cause <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, which may be severe.</dd>
<dt> </dt>
<dd>Certain medical conditions make you more likely to get <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</dd>
</dl>
<p><span class="Bold">Before you start taking OSENI:</span></p>
<p>Tell your doctor if you have ever had:</p>
<table width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First Toprule">
<td valign="top"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd>stones in your gallbladder (<span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span>)</dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd>a history of <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span></dd>
</dl></td>
</tr>
<tr class="Botrule Last">
<td valign="top"><dl>
<dt>•</dt>
<dd>kidney problems</dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd>liver problems</dd>
</dl></td>
<td valign="top"></td>
</tr>
</tbody>
</table>
<p>Stop taking OSENI and call your doctor right away if you have <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your stomach area (abdomen) that is severe and will not go away. The <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> may be felt going from your abdomen through to your back. The <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> may happen with or without <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. These may be symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<p><span class="Bold">What is OSENI? </span></p>
<dl>
<dt>•</dt>
<dd>OSENI contains 2 prescription <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines, alogliptin (NESINA) and pioglitazone (ACTOS).</dd>
<dt>•</dt>
<dd>OSENI is a prescription medicine used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</dd>
<dt>•</dt>
<dd>OSENI is not for people with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. </dd>
<dt>•</dt>
<dd>OSENI is not for people with <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> (increased <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> in blood or urine).</dd>
</dl>
<p>It is not known if OSENI is safe and effective in children under the age of 18. OSENI is not recommended for use in children.</p>
<p><span class="Bold">Who should not take OSENI?</span></p>
<p><span class="Bold">Do not take OSENI if you:</span></p>
<dl>
<dt>•</dt>
<dd>have severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></dd>
<dt>•</dt>
<dd>are allergic to alogliptin (NESINA), pioglitazone (ACTOS) or any ingredient in OSENI or have had a serious allergic (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>) reaction to alogliptin or pioglitazone. See the end of this Medication Guide for a complete list of the ingredients in OSENI.</dd>
<dt> </dt>
<dd>Symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to OSENI may include:</dd>
</dl>
<table width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, lips, throat and other areas on your skin</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>difficulty with swallowing or breathing</dd>
</dl></td>
</tr>
<tr class="Botrule Last">
<td valign="top"><dl>
<dt>o</dt>
<dd>raised, red areas on your skin (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>)</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, flaking or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span></dd>
</dl></td>
</tr>
</tbody>
</table>
<p>If you have these symptoms, stop taking OSENI and contact your doctor or go to the nearest hospital emergency room right away.</p>
<p><span class="Bold">What should I tell my doctor before and during treatment with OSENI? </span></p>
<p>Before you start taking OSENI, tell your doctor if you:</p>
<dl>
<dt>•</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></dd>
<dt>•</dt>
<dd>have a type of diabetic eye disease that causes <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the back of the eye (<span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>)</dd>
<dt>•</dt>
<dd>have kidney or liver problems </dd>
<dt>•</dt>
<dd>have or have had <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>)</dd>
<dt>•</dt>
<dd>have or have had cancer of the bladder</dd>
<dt>•</dt>
<dd>have other medical conditions</dd>
<dt>•</dt>
<dd>
<span class="Bold">are pregnant or plan to become pregnant.</span> It is not known if OSENI can harm your unborn baby. Talk to your doctor about the best way to control your blood sugar while you are pregnant or if you plan to become pregnant.</dd>
<dt>•</dt>
<dd>
<span class="Bold">are a premenopausal woman who does not have periods regularly or at all.</span> OSENI may increase your chance of becoming pregnant. Talk to your doctor about birth control choices while taking OSENI. Tell your doctor right away if you become pregnant while taking OSENI.</dd>
<dt>•</dt>
<dd>
<span class="Bold">are breastfeeding or plan to breastfeed.</span> It is not known whether OSENI passes into your breast milk and if it can harm your baby. You should not take OSENI if you breastfeed your baby. Talk with your doctor about the best way to feed your baby if you are taking OSENI.</dd>
</dl>
<p><span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and over-the-counter  medicines, vitamins and herbal supplements. </p>
<p>Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist before you start a new medicine.</p>
<p>OSENI may affect the way other medicines work, and other medicines may affect how OSENI works. Contact your doctor before you start or stop other types of medicines.</p>
<p><span class="Bold">How should I take OSENI?</span></p>
<dl>
<dt>•</dt>
<dd>Take OSENI exactly as your doctor tells you to take it.</dd>
<dt>•</dt>
<dd>Take OSENI 1 time each day with or without food.</dd>
<dt>•</dt>
<dd>Do not break or cut OSENI tablets before swallowing.</dd>
<dt>•</dt>
<dd>Your doctor may need to change your dose of OSENI to control your blood glucose. Do not change your dose unless told to do so by your doctor.</dd>
<dt>•</dt>
<dd>If you miss a dose, take it as soon as you remember. If you do not remember until it is time for your next dose, skip the missed dose and take the next dose at your regular time. <span class="Bold">Do not</span> take 2 doses of OSENI at the same time.</dd>
<dt>•</dt>
<dd>If you take too much OSENI, call your doctor or go to the nearest hospital emergency room right away.</dd>
<dt>•</dt>
<dd>If your body is under stress, such as from <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span> or surgery, the dose of your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines may need to be changed. Call your doctor right away. </dd>
<dt>•</dt>
<dd>Stay on your diet and exercise programs and check your blood sugar as your doctor tells you to.</dd>
<dt>•</dt>
<dd>Your doctor may do certain blood tests before you start OSENI and during treatment as needed. Your doctor may change your dose of OSENI based on the results of your blood tests due to how well your kidneys are working.</dd>
<dt>•</dt>
<dd>Your doctor will check your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with regular blood tests, including your blood sugar levels and your hemoglobin A1C.</dd>
<dt>•</dt>
<dd>Your doctor should check your eyes regularly while you take OSENI.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of OSENI?</span></p>
<p><span class="Bold">OSENI can cause serious side effects, including:</span></p>
<dl>
<dt>•</dt>
<dd>See “<span class="Bold">What is the most important information I should know about OSENI?</span>?</dd>
<dt>•</dt>
<dd>
<span class="Bold">Allergic (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>) reactions,</span> such as:</dd>
</dl>
<table width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, lips, throat and other areas on your skin</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>difficulty swallowing or breathing</dd>
</dl></td>
</tr>
<tr class="Botrule Last">
<td valign="top"><dl>
<dt>o</dt>
<dd>raised, red areas on your skin (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>)</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, flaking or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span></dd>
</dl></td>
</tr>
</tbody>
</table>
<p>If you have these symptoms, stop taking OSENI and contact your doctor right away.</p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Liver problems</span>. Call your doctor right away if you have unexplained symptoms such as:</dd>
</dl>
<table width="100%">
<col width="33%">
<col width="33%">
<col width="34%">
<tbody class="Headless">
<tr class="First Toprule">
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>unusual or unexplained <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></dd>
</dl></td>
</tr>
<tr class="Botrule Last">
<td valign="top"><dl>
<dt>o</dt>
<dd>loss of appetite</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>dark urine</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>yellowing of your skin or the whites of your eyes</dd>
</dl></td>
</tr>
</tbody>
</table>
<p><span class="Bold">    •   Broken bones (<span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>).</span> Usually in the hand, upper arm or foot in women. Talk to your doctor for advice on how to keep your bones healthy.</p>
<p><span class="Bold">    •   <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">Bladder cancer</span>.</span> There may be an increased chance of having <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> when you take OSENI. You should not take OSENI if you are receiving treatment for <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>. Tell your doctor right away if you have any of the following symptoms of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>:</p>
<table width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless"><tr class="First Last Toprule">
<td valign="top"><dl>
<dt>o</dt>
<dd>blood or a red color in your urine</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>an increased need to urinate</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> while you urinate</dd>
</dl></td>
</tr></tbody>
</table>
<p><span class="Bold">    •   Low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>).</span> If you take OSENI with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take OSENI. If you have symptoms of low blood sugar, you should check your blood sugar and treat if low, then call your doctor. Signs and symptoms of low blood sugar may include:</p>
<table width="100%">
<col width="19%">
<col width="20%">
<col width="21%">
<col width="21%">
<col width="19%">
<tbody class="Headless">
<tr class="First Toprule">
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> or <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">feeling jittery</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>change in mood</dd>
</dl></td>
</tr>
<tr class="Botrule Last">
<td valign="top"><dl>
<dt>o</dt>
<dd>fast heartbeat</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>change in vision</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
</dl></td>
<td valign="top"></td>
</tr>
</tbody>
</table>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Diabetic eye disease with <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in the back of the eye (<span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>).</span> Tell your doctor right away if you have any changes in your vision. Your doctor should check your eyes regularly.<dl>
<dt>•</dt>
<dd>
<span class="Bold">Release of an egg from an ovary in a woman (ovulation) leading to pregnancy.</span> Ovulation may happen when premenopausal women who do not have regular monthly periods take OSENI. This can increase your chance of getting pregnant. </dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Joint pain</span>.</span> Some people who take medicines called DPP-4 inhibitors, one of the medicines in OSENI, may develop <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> that can be severe.  Call your doctor if you have severe <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>.</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">The most common side effects of OSENI include</span> stuffy or <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span> and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>-like symptoms (<span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>).</p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of OSENI. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store OSENI?</span></p>
<dl>
<dt>•</dt>
<dd>Store OSENI at room temperature between 68°F to 77°F (20°C to 25°C).</dd>
<dt>•</dt>
<dd>Keep container tightly closed and protect from moisture and humidity.</dd>
</dl>
<p><span class="Bold">Keep OSENI and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of OSENI</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in the Medication Guide. Do not take OSENI for a condition for which it was not prescribed. Do not give OSENI to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about OSENI. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about OSENI that is written for health professionals.</p>
<p>For more information, go to www.oseni.com or call 1-877-TAKEDA-7 (1-877-825-3327).</p>
<p><span class="Bold">What are the ingredients in OSENI?</span></p>
<p><span class="Bold">Active ingredients:</span> alogliptin and pioglitazone.</p>
<p><span class="Bold">Inactive ingredients:</span> mannitol, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, magnesium stearate, and lactose monohydrate; the tablets are film-coated with hypromellose, polyethylene glycol, titanium dioxide, talc and ferric oxide (yellow and/or red) and are marked with red A1 or gray F1 printing ink.</p>
<p>Distributed by:<br><span class="Bold">Takeda Pharmaceuticals America, Inc.<br></span>Deerfield, IL 60015</p>
<p>OSENI, NESINA and ACTOS are trademarks of Takeda Pharmaceutical Company Limited registered with the U.S. Patent and Trademark Office and are used under license by Takeda Pharmaceuticals America, Inc.</p>
<p>©2013 – 2015 Takeda Pharmaceuticals America, Inc.</p>
<p>ALP008 R4</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.                        8/2015<br>  </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_b1bb2c5a-19c0-4c13-8174-0d76662f1502"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 12.5 mg/15 mg</span></p>
<p><span class="Bold">NDC</span> 64764-<span class="Bold">121</span>-03</p>
<p><span class="Bold">Oseni</span></p>
<p><span class="Bold">(alogliptin and</span><br><span class="Bold">pioglitazone) tablets</span></p>
<p><span class="Bold">12.5 mg/15 mg</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Dispense with</span><br><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">Takeda logo</span></p>
<p><span class="Bold">30 Tablets</span></p>
<div class="Figure">
<a name="id2313871"></a><img alt="12-5-15bottlelabel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55&amp;name=95b44edb-bd6f-471b-a1c7-44694551ecae-06.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_7309f56a-49e2-4ddc-8cc9-269142abc192"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 12.5 mg/30 mg</span></p>
<p><span class="Bold">NDC</span> 64764-<span class="Bold">123</span>-03</p>
<p><span class="Bold">Oseni</span></p>
<p><span class="Bold">(alogliptin and</span><br><span class="Bold">pioglitazone) tablets</span></p>
<p><span class="Bold">12.5 mg/30 mg</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Dispense with</span><br><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">Takeda logo</span></p>
<p><span class="Bold">30 Tablets</span></p>
<div class="Figure">
<a name="id2314559"></a><img alt="12-5-30bottlelabel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55&amp;name=95b44edb-bd6f-471b-a1c7-44694551ecae-07.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_48ffbfbc-c00b-4d2e-a840-578c33261f03"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 12.5 mg/45 mg</span></p>
<p><span class="Bold">NDC</span> 64764-<span class="Bold">124</span>-03</p>
<p><span class="Bold">Oseni</span></p>
<p><span class="Bold">(alogliptin and</span><br><span class="Bold">pioglitazone) tablets</span></p>
<p><span class="Bold">12.5 mg/45 mg</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Dispense with</span><br><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">Takeda logo</span></p>
<p><span class="Bold">30 Tablets</span></p>
<div class="Figure">
<a name="id2314562"></a><img alt="12-5-45bottlelabel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55&amp;name=95b44edb-bd6f-471b-a1c7-44694551ecae-08.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_38e1cbe7-5dd5-4cc8-ae9d-3fd2d01dff7e"></a><a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 25 mg/15 mg</span></p>
<p><span class="Bold">NDC</span> 64764-<span class="Bold">251</span>-03</p>
<p><span class="Bold">Oseni</span></p>
<p><span class="Bold">(alogliptin and</span><br><span class="Bold">pioglitazone) tablets</span></p>
<p><span class="Bold">25 mg/15 mg</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Dispense with</span><br><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">Takeda logo</span></p>
<p><span class="Bold">30 Tablets</span></p>
<div class="Figure">
<a name="id2314565"></a><img alt="25-15bottlelabel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55&amp;name=95b44edb-bd6f-471b-a1c7-44694551ecae-09.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_99e1559b-11ce-4de4-8c38-79257b008e1c"></a><a name="section-21"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 25 mg/30 mg</span></p>
<p><span class="Bold">NDC</span> 64764-<span class="Bold">253</span>-03</p>
<p><span class="Bold">Oseni</span></p>
<p><span class="Bold">(alogliptin and</span><br><span class="Bold">pioglitazone) tablets</span></p>
<p><span class="Bold">25 mg/30 mg</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Dispense with</span><br><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">Takeda logo</span></p>
<p><span class="Bold">30 Tablets</span></p>
<div class="Figure">
<a name="id2314568"></a><img alt="25-30bottlelabel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55&amp;name=95b44edb-bd6f-471b-a1c7-44694551ecae-10.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_5d5c9de8-b326-460e-badb-f904ef2656ca"></a><a name="section-22"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 25 mg/45 mg</span></p>
<p><span class="Bold">NDC</span> 64764-<span class="Bold">254</span>-03</p>
<p><span class="Bold">Oseni</span></p>
<p><span class="Bold">(alogliptin and</span><br><span class="Bold">pioglitazone) tablets</span></p>
<p><span class="Bold">25 mg/45 mg</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Dispense with</span><br><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">Takeda logo</span></p>
<p><span class="Bold">30 Tablets</span></p>
<div class="Figure">
<a name="id2314571"></a><img alt="25-45bottlelabel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55&amp;name=95b44edb-bd6f-471b-a1c7-44694551ecae-11.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OSENI 		
					</strong><br><span class="contentTableReg">alogliptin and pioglitazone tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-121</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALOGLIPTIN BENZOATE</strong> (ALOGLIPTIN) </td>
<td class="formItem">ALOGLIPTIN</td>
<td class="formItem">12.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PIOGLITAZONE HYDROCHLORIDE</strong> (PIOGLITAZONE) </td>
<td class="formItem">PIOGLITAZONE</td>
<td class="formItem">15 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE L)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYGLYCERYL-10 OLEATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AP;12;5;15</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-121-03</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-121-04</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64764-121-05</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:64764-121-06</td>
<td class="formItem">4  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022426</td>
<td class="formItem">01/25/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OSENI 		
					</strong><br><span class="contentTableReg">alogliptin and pioglitazone tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-123</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALOGLIPTIN BENZOATE</strong> (ALOGLIPTIN) </td>
<td class="formItem">ALOGLIPTIN</td>
<td class="formItem">12.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PIOGLITAZONE HYDROCHLORIDE</strong> (PIOGLITAZONE) </td>
<td class="formItem">PIOGLITAZONE</td>
<td class="formItem">30 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE L)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYGLYCERYL-10 OLEATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AP;12;5;30</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-123-03</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-123-04</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64764-123-05</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:64764-123-06</td>
<td class="formItem">4  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022426</td>
<td class="formItem">01/25/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OSENI 		
					</strong><br><span class="contentTableReg">alogliptin and pioglitazone tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-124</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALOGLIPTIN BENZOATE</strong> (ALOGLIPTIN) </td>
<td class="formItem">ALOGLIPTIN</td>
<td class="formItem">12.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PIOGLITAZONE HYDROCHLORIDE</strong> (PIOGLITAZONE) </td>
<td class="formItem">PIOGLITAZONE</td>
<td class="formItem">45 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE L)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYGLYCERYL-10 OLEATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AP;12;5;45</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-124-03</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-124-04</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64764-124-05</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:64764-124-06</td>
<td class="formItem">4  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022426</td>
<td class="formItem">01/25/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OSENI 		
					</strong><br><span class="contentTableReg">alogliptin and pioglitazone tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-251</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALOGLIPTIN BENZOATE</strong> (ALOGLIPTIN) </td>
<td class="formItem">ALOGLIPTIN</td>
<td class="formItem">25 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PIOGLITAZONE HYDROCHLORIDE</strong> (PIOGLITAZONE) </td>
<td class="formItem">PIOGLITAZONE</td>
<td class="formItem">15 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE L)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AP;25;15</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-251-03</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-251-04</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64764-251-05</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:64764-251-06</td>
<td class="formItem">4  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022426</td>
<td class="formItem">01/25/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OSENI 		
					</strong><br><span class="contentTableReg">alogliptin and pioglitazone tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-254</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALOGLIPTIN BENZOATE</strong> (ALOGLIPTIN) </td>
<td class="formItem">ALOGLIPTIN</td>
<td class="formItem">25 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PIOGLITAZONE HYDROCHLORIDE</strong> (PIOGLITAZONE) </td>
<td class="formItem">PIOGLITAZONE</td>
<td class="formItem">45 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE L)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AP;25;45</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-254-03</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-254-04</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64764-254-05</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:64764-254-06</td>
<td class="formItem">4  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022426</td>
<td class="formItem">01/25/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OSENI 		
					</strong><br><span class="contentTableReg">alogliptin and pioglitazone tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-253</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALOGLIPTIN BENZOATE</strong> (ALOGLIPTIN) </td>
<td class="formItem">ALOGLIPTIN</td>
<td class="formItem">25 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PIOGLITAZONE HYDROCHLORIDE</strong> (PIOGLITAZONE) </td>
<td class="formItem">PIOGLITAZONE</td>
<td class="formItem">30 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE L)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AP;25;30</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-253-03</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-253-04</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64764-253-05</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:64764-253-06</td>
<td class="formItem">4  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022426</td>
<td class="formItem">01/25/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Takeda Pharmaceuticals America, Inc.
							(830134016)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>113a9ea1-36e9-4196-8ee7-ca2186c6ec61</div>
<div>Set id: 4c619ed9-fe3e-4158-9938-80c6c3493d55</div>
<div>Version: 5</div>
<div>Effective Time: 20150831</div>
</div>
</div> <div class="DistributorName">Takeda Pharmaceuticals America, Inc.</div></p>
</body></html>
